WO2019006182A1 - VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF - Google Patents

VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF Download PDF

Info

Publication number
WO2019006182A1
WO2019006182A1 PCT/US2018/040115 US2018040115W WO2019006182A1 WO 2019006182 A1 WO2019006182 A1 WO 2019006182A1 US 2018040115 W US2018040115 W US 2018040115W WO 2019006182 A1 WO2019006182 A1 WO 2019006182A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acids
seq
aav
virion
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/040115
Other languages
English (en)
French (fr)
Inventor
David V. Schaffer
Leah C. Byrne
Timothy P. DAY
John G. Flannery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201880019175.3A priority Critical patent/CN110461368A/zh
Priority to JP2019568621A priority patent/JP7744659B2/ja
Priority to CA3053154A priority patent/CA3053154A1/en
Priority to KR1020197027085A priority patent/KR102766238B1/ko
Priority to KR1020257003821A priority patent/KR20250023600A/ko
Priority to EP18822630.2A priority patent/EP3645052A4/en
Priority to AU2018290954A priority patent/AU2018290954B2/en
Priority to MX2019010910A priority patent/MX2019010910A/es
Priority to US16/486,681 priority patent/US20200121746A1/en
Priority to BR112019019015A priority patent/BR112019019015A2/pt
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2019006182A1 publication Critical patent/WO2019006182A1/en
Anticipated expiration legal-status Critical
Priority to US18/167,598 priority patent/US12310997B2/en
Priority to JP2023110850A priority patent/JP2023126919A/ja
Priority to AU2023248082A priority patent/AU2023248082B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Definitions

  • Photoreceptors which lie at the back of the retina, respond to the absorption of photons, initiating a stream of signal processing that passes through second and third order neurons in the retina, including bipolar, horizontal and amacrine cells.
  • Retinal pigment epithelium (RPE) cells which lie underneath photoreceptors, promote the regeneration of the photon-detecting molecule, 11-cis retinal, via the visual cycle pathway and hence are essential for promoting this photoreceptor function.
  • Retinal ganglion cells (RGCs) in the inner retina receive visual signals from third order neurons, and communicate the visual signals in the form of action potentials to the brain.
  • bipolar cells and other cells result in a breakdown of visual signal processing and retinal degeneration.
  • Many of the mutations underlying retinal degenerative disease result in the death of photoreceptor and RPE cells.
  • Adeno-associated virus belongs to the Parvoviridae family and Dependovinis genus, whose members require co-infection with a helper virus such as adenovirus to promote replication, and AAV establishes a latent infection in the absence of a helper.
  • Virions are composed of a 25 nm icosahedral capsid encompassing a 4.7 kb single-stranded DNA genome with two open reading frames: rep and cap.
  • the non-structural rep gene encodes four regulatory proteins essential for viral replication, whereas cap encodes three structural proteins (VP 1-3) that assemble into a 60-mer capsid shell.
  • This viral capsid mediates the ability of AAV vectors to overcome many of the biological barriers of viral transduction-incruding ceil surface receptor binding, endocytosis, intracellular trafficking, and unpackaging in the nucleus.
  • the present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid.
  • AAV adeno-associated virus
  • rAAV recombinant adeno-associated virus
  • the present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
  • FIG. 1 provides a schematic depiction of the directed evolution methodology used to develop primate retinal AAV variants.
  • FIG. 2 provides a table of peptide insertions and peptide replacements in variant AAV capsids.
  • FIG. 3A-3C provide amino acid sequences of exemplary guide-RNA-directed endonucleases.
  • FIG. 4 provides an amino acid sequence of AAV2 capsid protein VPl. Amino acids 587 and 588
  • FIG. 5 provides amino acid sequences corresponding to amino acids 570-610 of AAV capsid protein VPl of various AAV serotypes.
  • FIG. 6A-6C provide an alignment of amino acid sequences of AAV capsid protein loop IV (GH loop) regions. Insertion sites are shown in bold and underlining.
  • FIG. 7A-7V provide amino acid sequences of exemplary heterologous gene products.
  • FIG. 8A-8B provide amino acid sequences of AAV4 capsid (FIG. 8A) and an ancestral AAV capsid (FIG. 8B).
  • FIG. 9 provides Table 1.
  • Table 1 provides a ranking of primate -derived variants and controls recovered from photoreceptors following injection of a green fluorescent protein (GFP) -Barcode library.
  • GFP green fluorescent protein
  • FIG. 10 provides Table 2.
  • Table 2 provides a ranking of primate-derived variants and controls recovered from RPE cells following injection of a GFP-Barcode library.
  • FIG. 11 depicts GFP expression of GFP-barcoded libraries in primate retina.
  • FIG. 12A-12F depict directed evolution of AAV in primate retina.
  • the sequences in FIG. 12F from top to bottom are set forth in SEQ ID NOs: 117-135.
  • FIG. 13A-13Q depict validation of evolved AAV variants in primate retina.
  • retinal cell can refer herein to any of the cell types that comprise the retina, such as retinal ganglion cells; amacrine cells; horizontal cells; bipolar cells; photoreceptor cells including rods and cones; Muller glial cells; astrocytes (e.g., a retinal astrocyte); and retinal pigment epithelium.
  • AAV is an abbreviation for adeno-associated virus, and may be used to refer to the virus itself or derivatives thereof. The term covers all subtypes and both naturally occurring and recombinant forms, except where required otherwise.
  • the abbreviation “rAAV” refers to recombinant adeno-associated virus, also referred to as a recombinant AAV vector (or "rAAV vector”).
  • AAV includes AAV type 1 (AAV-1), AAV type 2 (AAV-2), AAV type 3 (AAV-3), AAV type 4 (AAV-4), AAV type 5 (AAV-5), AAV type 6 (AAV-6), AAV type 7 (AAV-7), AAV type 8 (AAV-8), AAV type 9 (AAV-9), AAV type 10 (AAV-10), AAV type 11 (AAV-11), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and ovine AAV. See, e.g., Mori et al. (2004) Virology 330:375.
  • AAV also includes chimeric AAV.
  • Prime AAV refers to AAV isolated from a primate
  • non-primate AAV refers to AAV isolated from a non-primate mammal
  • bovine AAV refers to AAV isolated from a bovine mammal (e.g., a cow), etc.
  • rAAV vector refers to an AAV vector comprising a polynucleotide sequence not of AAV origin (i.e., a polynucleotide heterologous to AAV), typically a sequence of interest for the genetic transformation of a cell.
  • the heterologous polynucleotide is flanked by at least one, and generally by two AAV inverted terminal repeat sequences (ITRs).
  • ITRs AAV inverted terminal repeat sequences
  • An "AAV virus” or “AAV viral particle” or “rAAV vector particle” refers to a viral particle composed of at least one AAV capsid protein (typically by all of the capsid proteins of a wild- type AAV) and an encapsidated polynucleotide rAAV vector. If the particle comprises a heterologous polynucleotide (i.e. a polynucleotide other than a wild-type AAV genome, such as a transgene to be delivered to a mammalian cell), it is typically referred to as an "rAAV vector particle” or simply an "rAAV vector". Thus, production of rAAV particle necessarily includes production of rAAV vector, as such a vector is contained within an rAAV particle.
  • AAV "rep” and “cap” genes refer to polynucleotide sequences encoding replication and encapsidation proteins of adeno-associated virus. AAV rep and cap are referred to herein as AAV "packaging genes. "
  • a "helper virus” for AAV refers to a virus that allows AAV (e.g. wild-type AAV) to be
  • helper viruses for AAV are known in the art, including adenoviruses, herpesviruses and poxviruses such as vaccinia.
  • the adenoviruses encompass a number of different subgroups, although Adenovirus type 5 of subgroup C is most commonly used.
  • Numerous adenoviruses of human, non-human mammalian and avian origin are known and available from depositories such as the ATCC.
  • Viruses of the herpes family include, for example, herpes simplex viruses (HSV) and Epstein-Barr viruses (EBV), as well as cytomegaloviruses (CMV) and pseudorabies viruses (PRV); which are also available from depositories such as ATCC.
  • HSV herpes simplex viruses
  • EBV Epstein-Barr viruses
  • CMV cytomegaloviruses
  • PRV pseudorabies viruses
  • Helper virus function(s) refers to function(s) encoded in a helper virus genome which allow AAV replication and packaging (in conjunction with other requirements for replication and packaging described herein). As described herein, "helper virus function” may be provided in a number of ways, including by providing helper virus or providing, for example, polynucleotide sequences encoding the requisite function(s) to a producer cell in trans.
  • an "infectious" virus or viral particle is one that comprises a polynucleotide component which it is capable of delivering into a cell for which the viral species is tropic. The term does not necessarily imply any replication capacity of the virus.
  • an "infectious" virus or viral particle is one that can access a target cell, can infect a target cell, and can express a heterologous nucleic acid in a target cell.
  • infectivity refers to the ability of a viral particle to access a target cell, infect a target cell, and express a heterologous nucleic acid in a target cell. Infectivity can refer to in vitro infectivity or in vivo infectivity.
  • Viral infectivity can be expressed as the ratio of infectious viral particles to total viral particles.
  • Total viral particles can be expressed as the number of viral genome (vg) copies.
  • the ability of a viral particle to express a heterologous nucleic acid in a cell can be referred to as "transduction.”
  • the ability of a viral particle to express a heterologous nucleic acid in a cell can be assayed using a number of techniques, including assessment of a marker gene, such as a green fluorescent protein (GFP) assay (e.g., where the virus comprises a nucleotide sequence encoding GFP), where GFP is produced in a cell infected with the viral particle and is detected and/or measured; or the measurement of a produced protein, for example by an enzyme-linked immunosorbent assay (ELISA).
  • GFP green fluorescent protein
  • Viral infectivity can be expressed as the ratio of infectious viral particles to total viral particles.
  • Methods of determining the ratio of infectious viral particle to total viral particle are known in the art. See, e.g., Grainger et al. (2005) Mol. Ther. 11:S337 (describing a TCID50 infectious titer assay); and Zolotukhin et al. (1999) Gene Ther. 6:973.
  • a "replication-competent" virus e.g. a replication-competent AAV refers to a phenotypically wild-type virus that is infectious, and is also capable of being replicated in an infected cell (i.e. in the presence of a helper virus or helper virus functions).
  • replication competence generally requires the presence of functional AAV packaging genes.
  • rAAV vectors as described herein are replication-incompetent in mammalian cells (especially in human cells) by virtue of the lack of one or more AAV packaging genes.
  • rAAV vector preparations as described herein are those which contain few if any replication competent AAV (rcAAV, also referred to as RCA) (e.g., less than about 1 rcAAV per 10 2 rAAV particles, less than about 1 rcAAV per 10 4 rAAV particles, less than about 1 rcAAV per 10 s rAAV particles, less than about 1 rcAAV per 10 12 rAAV particles, or no rcAAV).
  • rcAAV also referred to as RCA
  • polynucleotide refers to a polymeric form of nucleotides of any length, including deoxyribonucleotides or ribonucleotides, or analogs thereof.
  • a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, and may be interrupted by non-nucleotide components. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer.
  • polynucleotide refers interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form.
  • a polynucleotide or polypeptide has a certain percent "sequence identity" to another
  • sequence similarity can be determined in a number of different manners.
  • sequences can be aligned using the methods and computer programs, including BLAST, available over the world wide web at ncbi.nlm.nih.gov/BLAST/.
  • FASTA is Another alignment algorithm, available in the Genetics Computing Group (GCG) package, from Madison, Wisconsin, USA, a wholly owned subsidiary of Oxford Molecular Group, Inc.
  • GCG Genetics Computing Group
  • the program has default parameters determined by the sequences inputted to be compared.
  • the sequence identity is determined using the default parameters determined by the program. This program is available also from Genetics Computing Group (GCG) package, from Madison, Wisconsin, USA.
  • GCG Genetics Computing Group
  • FastDB is described in Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp. 127-149, 1988, Alan R. Liss, Inc. Percent sequence identity is calculated by FastDB based upon the following parameters:
  • a "gene” refers to a polynucleotide containing at least one open reading frame that is capable of encoding a particular protein after being transcribed and translated.
  • guide RNA refers to an RNA that comprises: i) an "activator"
  • nucleotide sequence that binds to a guide RNA-directed endonuclease e.g., a class 2
  • CRISPR/Cas endonuclease such as a type II, type V, or type VI CRISPR/Cas endonuclease
  • a "targeter” nucleotide sequence that comprises a nucleotide sequence that hybridizes with a target nucleic acid.
  • the "activator" nucleotide sequence and the "targeter” nucleotide sequence can be on separate RNA molecules (e.g., a "dual-guide RNA"); or can be on the same RNA molecule (a "single-guide RNA").
  • a "small interfering” or “short interfering RNA” or siRNA is an RNA duplex of nucleotides that is targeted to a gene interest (a "target gene”).
  • An “RNA duplex” refers to the structure formed by the complementary pairing between two regions of an RNA molecule.
  • siRNA is "targeted” to a gene in that the nucleotide sequence of the duplex portion of the siRNA is complementary to a nucleotide sequence of the targeted gene.
  • the length of the duplex of siRNAs is less than 30 nucleotides.
  • the duplex can be 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 or 10 nucleotides in length.
  • the length of the duplex is 19-25 nucleotides in length.
  • the RNA duplex portion of the siRNA can be part of a hairpin structure.
  • the hairpin structure may contain a loop portion positioned between the two sequences that form the duplex.
  • the loop can vary in length. In some embodiments the loop is 5, 6, 7, 8, 9, 10, 11, 12 or 13 nucleotides in length.
  • the hairpin structure can also contain 3' or 5' overhang portions. In some embodiments, the overhang is a 3' or a 5' overhang 0, 1, 2, 3, 4 or 5 nucleotides in length.
  • microRNA refers to any type of interfering RNAs, including but not limited to, endogenous microRNAs and artificial microRNAs (e.g., synthetic miRNAs).
  • Endogenous microRNAs are small RNAs naturally encoded in the genome which are capable of modulating the productive utilization of mRNA.
  • An artificial microRNA can be any type of RNA sequence, other than endogenous microRNA, which is capable of modulating the activity of an mRNA.
  • a microRNA sequence can be an RNA molecule composed of any one or more of these sequences.
  • MicroRNA or "miRNA" sequences have been described in publications such as Lim, et al., 2003, Genes & Development, 17, 991-1008, Lim et al., 2003, Science, 299, 1540, Lee and Ambrose, 2001, Science, 294, 862, Lau et al., 2001, Science 294, 858-861, Lagos- Quintana et al., 2002, Current Biology, 12, 735-739, Lagos -Quintana et al., 2001, Science, 294, 853-857, and Lagos-Quintana et al., 2003, RNA, 9, 175-179.
  • microRNAs include any RNA that is a fragment of a larger RNA or is a miRNA, siRNA, stRNA, sncRNA, tncRNA, snoRNA, smRNA, shRNA, snRNA, or other small non-coding RNA. See, e.g., US Patent Applications 20050272923, 20050266552, 20050142581, and 20050075492.
  • a "microRNA precursor” refers to a nucleic acid having a stem-loop structure with a microRNA sequence incorporated therein.
  • a “mature microRNA” includes a microRNA that has been cleaved from a microRNA precursor (a "pre-miRNA”), or that has been synthesized (e.g., synthesized in a laboratory by cell-free synthesis), and has a length of from about 19 nucleotides to about 27 nucleotides, e.g., a mature microRNA can have a length of 19 nt, 20 nt, 21 nt, 22 nt, 23 nt, 24 nt, 25 nt, 26 nt, or 27 nt.
  • a mature microRNA can bind to a target mRNA and inhibit translation of the target mRNA.
  • Recombinant as applied to a polynucleotide means that the polynucleotide is the product of various combinations of cloning, restriction or ligation steps, and other procedures that result in a construct that is distinct from a polynucleotide found in nature.
  • a recombinant virus is a viral particle comprising a recombinant polynucleotide. The terms respectively include replicates of the original polynucleotide construct and progeny of the original virus construct.
  • control element or "control sequence” is a nucleotide sequence involved in an interaction of molecules that contributes to the functional regulation of a polynucleotide, including replication, duplication, transcription, splicing, translation, or degradation of the polynucleotide. The regulation may affect the frequency, speed, or specificity of the process, and may be enhancing or inhibitory in nature.
  • Control elements known in the art include, for example, transcriptional regulatory sequences such as promoters and enhancers.
  • a promoter is a DNA region capable under certain conditions of binding RNA polymerase and initiating transcription of a coding region usually located downstream (in the 3' direction) from the promoter.
  • “Operatively linked” or “operably linked” refers to a juxtaposition of genetic elements, wherein the elements are in a relationship permitting them to operate in the expected manner. For instance, a promoter is operatively linked to a coding region if the promoter helps initiate transcription of the coding sequence. There may be intervening residues between the promoter and coding region so long as this functional relationship is maintained.
  • An "expression vector” is a vector comprising a region which encodes a polypeptide of interest, and is used for effecting the expression of the protein in an intended target cell.
  • An expression vector also comprises control elements operatively linked to the encoding region to facilitate expression of the protein in the target.
  • the combination of control elements and a gene or genes to which they are operably linked for expression is sometimes referred to as an "expression cassette,” a large number of which are known and available in the art or can be readily constructed from components that are available in the art.
  • Heterologous means derived from a genotypically distinct entity from that of the rest of the entity to which it is being compared.
  • a polynucleotide introduced by genetic engineering techniques into a plasmid or vector derived from a different species is a
  • heterologous polynucleotide A promoter removed from its native coding sequence and operatively linked to a coding sequence with which it is not naturally found linked is a heterologous promoter.
  • a heterologous promoter For example, an rAAV that includes a heterologous nucleic acid encoding a heterologous gene product is an rAAV that includes a nucleic acid not normally included in a naturally-occurring, wild-type AAV, and the encoded heterologous gene product is a gene product not normally encoded by a naturally-occurring, wild- type AAV.
  • a variant AAV capsid protein that comprises a heterologous peptide inserted into the GH loop of the capsid protein is a variant AAV capsid protein that includes an insertion of a peptide not normally included in a naturally-occurring, wild- type AAV.
  • genetic alteration and “genetic modification” (and grammatical variants thereof), are used interchangeably herein to refer to a process wherein a genetic element (e.g., a
  • polynucleotide is introduced into a cell other than by mitosis or meiosis.
  • the element may be heterologous to the cell, or it may be an additional copy or improved version of an element already present in the cell.
  • Genetic alteration may be effected, for example, by transfecting a cell with a recombinant plasmid or other polynucleotide through any process known in the art, such as electroporation, calcium phosphate precipitation, or contacting with a polynucleotide- liposome complex. Genetic alteration may also be effected, for example, by transduction or infection with a DNA or RNA virus or viral vector.
  • the genetic element is introduced into a chromosome or mini-chromosome in the cell; but any alteration that changes the phenotype and/or genotype of the cell and its progeny is included in this term.
  • a cell is said to be “stably” altered, transduced, genetically modified, or transformed with a genetic sequence if the sequence is available to perform its function during extended culture of the cell in vitro.
  • a cell is “heritably” altered (genetically modified) in that a genetic alteration is introduced which is also inheritable by progeny of the altered cell.
  • polypeptide refers to polymers of amino acids of any length.
  • the terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, phosphorylation, or conjugation with a labeling component.
  • Polypeptides such as anti- angiogenic polypeptides, neuroprotective polypeptides, and the like, when discussed in the context of delivering a gene product to a mammalian subject, and compositions therefor, refer to the respective intact polypeptide, or any fragment or genetically engineered derivative thereof, which retains the desired biochemical function of the intact protein.
  • references to nucleic acids encoding anti-angiogenic polypeptides, nucleic acids encoding neuroprotective polypeptides, and other such nucleic acids for use in delivery of a gene product to a mammalian subject include polynucleotides encoding the intact polypeptide or any fragment or genetically engineered derivative possessing the desired biochemical function.
  • An "isolated" plasmid, nucleic acid, vector, virus, virion, host cell, or other substance refers to a preparation of the substance devoid of at least some of the other components that may also be present where the substance or a similar substance naturally occurs or is initially prepared from.
  • an isolated substance may be prepared by using a purification technique to enrich it from a source mixture. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured in relation to a second, potentially interfering substance present in the source mixture. Increasing enrichments of the embodiments of this invention are increasingly more isolated.
  • An isolated plasmid, nucleic acid, vector, virus, host cell, or other substance is in some embodiments purified, e.g., from about 80% to about 90% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, or at least about 99%, or more, pure.
  • treatment refers to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease.
  • Treatment covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease or at risk of acquiring the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.
  • the terms "individual,” “host,” “subject,” and “patient” are used interchangeably herein, and refer to a mammal, including, but not limited to, human and non-human primates, including simians and humans; mammalian sport animals (e.g., horses, camels, etc.); mammalian farm animals (e.g., sheep, goats, cows, etc.); mammalian pets (dogs, cats, etc.); and rodents (e.g., mice, rats, etc.). In some cases, the individual is a human.
  • mammalian sport animals e.g., horses, camels, etc.
  • mammalian farm animals e.g., sheep, goats, cows, etc.
  • mammalian pets dogs, cats, etc.
  • rodents e.g., mice, rats, etc.
  • an rAAV virion includes a plurality of such virions and reference to “the variant capsid protein” includes reference to one or more variant capsid proteins and equivalents thereof known to those skilled in the art, and so forth.
  • the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
  • the present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid.
  • AAV adeno-associated virus
  • rAAV recombinant adeno-associated virus
  • the present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
  • the present disclosure also provides methods of modifying a target nucleic acid present in a retinal cell.
  • the present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater infectivity of a retinal cell compared to wild-type AAV; and where the rAAV virions comprise a heterologous nucleic acid.
  • the rAAV virions exhibit increased ability to cross a barrier between intravitreal fluid and retinal cells.
  • the rAAV virions exhibit greater infectivity of a retinal cell, compared to the infectivity of a corresponding wild-type AAV for the retinal cell.
  • the retinal cell can be a photoreceptor (e.g., rods; cones), a retinal ganglion cell (RGC), a Muller cell (a Muller glial cell), an astrocyte (e.g., a retinal astrocyte), a bipolar cell, an amacrine cell, a horizontal cell, or a retinal pigment epithelium (RPE) cell.
  • the present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating an ocular disease.
  • the present disclosure provides an rAAV virion with an altered capsid protein, where the rAAV virion exhibits at least 5-fold increased localization to one or more of the inner nuclear layer, the outer nuclear layer, the photoreceptor layer, the ganglion cell layer, and the retinal pigment epithelium, compared to the extent of localization to the inner nuclear layer, the outer nuclear layer, the photoreceptor layer, the ganglion cell layer, or the retinal pigment epithelium, by an AAV virion comprising the corresponding parental AAV capsid protein; and where the rAAV virions comprise a heterologous nucleic acid.
  • the present disclosure provides a variant AAV capsid protein.
  • a variant AAV capsid protein of the present disclosure is altered, compared to a wild-type or other reference AAV capsid protein. Alterations include insertions and swaps (e.g., replacements of a contiguous stretch of amino acids with a different contiguous stretch of amino acids).
  • a variant AAV capsid protein of the present disclosure comprises an insertion of a heterologous peptide of from 5 amino acids to 20 amino acids in length in an insertion site in a surface-accessible (e.g., solvent-accessible) portion of a parental AAV capsid protein, such that the variant capsid protein, when present in an AAV virion, confers increased infectivity of a retinal cell compared to the infectivity of the retinal cell by an AAV virion comprising the corresponding parental AAV capsid protein, particularly when the AAV virion is injected intravitreally.
  • a heterologous peptide of from 5 amino acids to 20 amino acids in length in an insertion site in a surface-accessible (e.g., solvent-accessible) portion of a parental AAV capsid protein
  • a variant AAV capsid protein of the present disclosure when present in an AAV virion, confers increased ability of the AAV virion to cross a barrier between the intravitreal fluid ("vitreous") and a retinal cell, where such barriers include, e.g., the inner limiting membrane (ILM), the extracellular matrix of the retina, the cell membranes of the retinal cells themselves, inner nuclear layer, the outer nuclear layer, the photoreceptor layer, the ganglion cell layer, and the retinal pigment epithelium.
  • the retinal cell is a Muller cell.
  • Other retinal cells include amacrine cells, bipolar cells, and horizontal cells.
  • an “insertion of from about 5 amino acids to about 20 amino acids” is also referred to herein as a "peptide insertion” (e.g., a heterologous peptide insertion).
  • a “corresponding parental AAV capsid protein” refers to an AAV capsid protein of the same AAV serotype, without a heterologous peptide insertion.
  • the variant AAV capsid comprises a single heterologous peptide insert of from 5 amino acids to 20 amino acids (e.g., from 5 to 7, from 7 to 10, from 10 to 12, from 12 to 15, or from 15 to 20 amino acids) in length.
  • An alteration in an AAV capsid can also be a swap, e.g., a replacement of a contiguous stretch of amino acids with a heterologous peptide.
  • a replacement is an insertion of a heterologous peptide in place of a contiguous stretch of amino acids.
  • a variant AAV capsid protein of the present disclosure comprises replacement of a contiguous stretch of amino acids with a heterologous peptide of from 5 amino acids to 20 amino acids in length in a site in a surface-accessible (e.g., solvent-accessible) portion of a parental AAV capsid protein, such that the variant capsid protein, when present in an AAV virion, confers increased infectivity of a retinal cell compared to the infectivity of the retinal cell by an AAV virion comprising the corresponding parental AAV capsid protein, particularly when the AAV virion is injected intravitreally.
  • a surface-accessible (e.g., solvent-accessible) portion of a parental AAV capsid protein such that the variant capsid protein, when present in an AAV virion, confers increased infectivity of a retinal cell compared to the infectivity of the retinal cell by an AAV virion comprising the corresponding parental AAV capsid protein, particularly when the AAV virion is
  • a variant AAV capsid protein of the present disclosure when present in an AAV virion, confers increased ability of the AAV virion to cross a barrier between the intravitreal fluid ("vitreous") and a retinal cell, where such barriers include, e.g., ILM, the extracellular matrix of the retina, the cell membranes of the retinal cells themselves, inner nuclear layer, the outer nuclear layer, the photoreceptor layer, the ganglion cell layer, and the retinal pigment epithelium.
  • the retinal cell is a Muller cell.
  • Other retinal cells include amacrine cells, bipolar cells, and horizontal cells.
  • a “replacement of from about 5 amino acids to about 20 amino acids” is also referred to herein as a “peptide swap” (e.g., a replacement of a contiguous stretch of amino acids with a heterologous peptide).
  • a “corresponding parental AAV capsid protein” refers to an AAV capsid protein of the same AAV serotype, without a heterologous peptide. In some instances, the variant AAV capsid comprises a single
  • heterologous peptide replacement of from 5 amino acids to 20 amino acids (e.g., from 5 to 7, from 7 to 10, from 10 to 12, from 12 to 15, or from 15 to 20 amino acids) in length.
  • insertion refers to both insertion of a heterologous peptide without replacement of a contiguous stretch of amino acids, and to insertion of a heterologous peptide that replaces a contiguous stretch of amino acids.
  • the insertion site is in the GH loop, or loop IV, of the AAV capsid protein, e.g., in a solvent- accessible portion of the GH loop, or loop IV, of the AAV capsid protein.
  • the insertion site can be within amino acids 411-650 of an AAV capsid protein, as depicted in FIG. 6A-6C.
  • the insertion site can be within amino acids 570-611 of AAV2, within amino acids 571-612 of AAV1, within amino acids 560-601 of AAV5, within amino acids 571 to 612 of AAV6, within amino acids 572 to 613 of AAV7, within amino acids 573 to 614 of AAV8, within amino acids 571 to 612 of AAV9, or within amino acids 573 to 614 of AAV10, as depicted in FIG. 5.
  • the insertion site is between amino acids 588 and 589 of an AAV2 capsid protein, or a corresponding insertion site in an AAV of a different serotype.
  • the insertion site is between amino acids 587 and 588 of an AAV2 capsid protein, or a corresponding insertion site in an AAV of a different serotype. In some cases, the insertion site is between amino acids 575 and 576 of an AAV2 capsid protein, or a corresponding insertion site in an AAV of a different serotype. In some cases, the insertion site is between amino acids 584 and 585 of an AAV2 capsid protein, or a corresponding insertion site in an AAV of a different serotype. In some cases, the insertion site is between amino acids 590 and 591 of an AAV2 capsid protein, or a corresponding insertion site in an AAV of a different serotype.
  • the insertion site is between amino acids 584 and 585 of an AAV4 capsid protein, or a corresponding insertion site in an AAV of a different serotype. In some cases, the insertion site is between amino acids 575 and 576 of an AAV5 capsid protein, or a corresponding insertion site in an AAV of a different serotype. In some cases, the site for replacement is between amino acids 584 and 598 of an AAV2 capsid protein, or a corresponding site in an AAV of a different serotype.
  • a heterologous peptide of from about 5 amino acids to about 20 amino acids is inserted in an insertion site in the GH loop or loop IV of the capsid protein relative to a corresponding parental AAV capsid protein.
  • the insertion site can be between amino acids 587 and 588 of AAV2, or between amino acids 588 and 589 of AAV2, or the corresponding positions of the capsid subunit of another AAV serotype. It should be noted that the insertion site 587/588 is based on an AAV2 capsid protein.
  • a heterologous peptide of 5 amino acids to about 20 amino acids (e.g., from 5 to 7, from 7 to 10, from 10 to 12, from 12 to 15, or from 15 to 20 amino acids) in length can be inserted in a corresponding site in an AAV serotype other than AAV2 (e.g., AAV8, AAV9, etc.).
  • AAV8 AAV9
  • Those skilled in the art would know, based on a comparison of the amino acid sequences of capsid proteins of various AAV serotypes, where an insertion site "corresponding to amino acids 587-588 of AAV2" would be in a capsid protein of any given AAV serotype. Sequences corresponding to amino acids 570-611 of capsid protein VP1 of AAV2 (see FIG.
  • GenBank Accession No. NP_049542 for AAV1; GenBank Accession No. NP_044927 for AAV4; GenBank Accession No. AAD13756 for AAV5; GenBank Accession No. AAB95459 for AAV6; GenBank Accession No. YP_077178 for AAV7; GenBank Accession No.
  • GenBank Accession No. AAS99264 for AAV9 GenBank Accession No. AAT46337 for AAV10
  • GenBank Accession No. AAO88208 for AAVrhlO. See, e.g., Santiago-Ortiz et al. (2015) Gene Ther. 22:934 for ancestral AAV capsid.
  • the insertion site can be between amino acids 587 and 588 of AAV2, between amino acids 590 and 591 of AAV1, between amino acids 575 and 576 of AAV5, between amino acids 590 and 591 of AAV6, between amino acids 589 and 590 of AAV7, between amino acids 590 and 591 of AAV8, between amino acids 588 and 589 of AAV9, between amino acids 588 and 589 of AAV10, or between amino acids 585 and 586 of AAV4.
  • the insertion sites are underlined in FIG. 5; the amino acid numbering is based on the numbering depicted in FIG. 5.
  • a subject capsid protein includes a GH loop comprising an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to an amino acid sequence set forth in FIG. 6A-6C; and having an insertion of a heterologous peptide of from 5 to 20 amino acids (e.g., from 5 to 7, from 7 to 10, from 10 to 12, from 12 to 15, or from 15 to 20 amino acids) in length.
  • a variant AAV capsid protein of the present disclosure comprises a replacement, or substitution, of a segment, or sequence of consecutive amino acids, in a surface-accessible (e.g., solvent-accessible) portion of a parental AAV capsid, such that the variant capsid protein, when present in an AAV virion, confers increased infectivity of a retinal cell compared to the infectivity of the retinal cell by an AAV virion comprising the corresponding parental AAV capsid protein, particularly when the AAV virion is injected intravitreally.
  • a surface-accessible (e.g., solvent-accessible) portion of a parental AAV capsid such that the variant capsid protein, when present in an AAV virion, confers increased infectivity of a retinal cell compared to the infectivity of the retinal cell by an AAV virion comprising the corresponding parental AAV capsid protein, particularly when the AAV virion is injected intravitreally.
  • a subject variant AAV capsid protein comprising the sequence substitution when present in an AAV virion, confers increased ability of the AAV virion to cross a barrier between the vitreous and a retinal cell, where such barriers include, e.g., the inner limiting membrane, the extracellular matrix of the retina, and the cell membranes of the retinal cells themselves.
  • a "replacement of from about 5 consecutive amino acids to about 25 consecutive amino acids” is also referred to herein as a “loop swap" (i.e. a heterologous peptide substitution).
  • a "corresponding parental AAV capsid protein” in such instances refers to an AAV capsid protein of the same AAV serotype, without the subject loop swap.
  • the variant AAV capsid comprises a heterologous peptide substitution of from 5 contiguous amino acids to 25 contiguous amino acids, e.g. from 5 to 9, from 9 to 11, from 10 to 15, from 15 to 20, or from 20 to 25 amino acids in length.
  • a heterologous peptide of from about 5 amino acids to about 25 amino acids is substituted in for an equivalent number of consecutive amino acids in a corresponding parental AAV capsid protein.
  • the substitution begins at around amino acid 588 of AAV2, or the corresponding position of the capsid subunit of another AAV serotype, and ends at around amino acid 598 of AAV2 or the corresponding position of the capsid subunit of another AAV serotype. It should be noted that the residues 588-598 are based on an AAV2 VP1 capsid protein.
  • a heterologous peptide of 5 amino acids to about 25 amino acids in length can be substituted into a corresponding site in an AAV serotype other than AAV2 (e.g., AAV8, AAV9, etc.).
  • AAV8 AAV9
  • Those skilled in the art would know, based on a comparison of the amino acid sequences of capsid proteins of various AAV serotypes, where a substitution site "corresponding to amino acids 588-598 of AAV2" would be in a capsid protein of any given AAV serotype.
  • the amino acid residue corresponding to amino acids 588-598 of capsid protein VP1 of AAV2 (see FIG. 4) in various AAV serotypes are shown in FIG. 5. See, e.g., GenBank Accession No. NP_049542 for AAV1 ; GenBank Accession No. NP_044927 for AAV4; GenBank Accession No.
  • GenBank Accession No. AAB95459 for AAV6 GenBank Accession No. YP_077178 for AAV7; GenBank Accession No. YP_077180 for AAV8; GenBank Accession No.
  • a heterologous peptide of from about 5 amino acids to about 25 amino acids is substituted in for an equivalent number of consecutive amino acids in a corresponding parental AAV capsid protein.
  • the substitution begins at around amino acid 585 of AAV2, or the corresponding position of the capsid subunit of another AAV serotype, and ends at around amino acid 598 of AAV2 or the corresponding position of the capsid subunit of another AAV serotype. It should be noted that the residues 585-598 are based on an AAV2 VP1 capsid protein.
  • a heterologous peptide of 5 amino acids to about 25 amino acids in length can be substituted into a corresponding site in an AAV serotype other than AAV2 (e.g., AAV8, AAV9, etc.).
  • AAV8 AAV9
  • Those skilled in the art would know, based on a comparison of the amino acid sequences of capsid proteins of various AAV serotypes, where a substitution site "corresponding to amino acids 585-598 of AAV2" would be in a capsid protein of any given AAV serotype.
  • the amino acid residue corresponding to amino acids 585-598 of capsid protein VP1 of AAV2 (see FIG. 4) in various AAV serotypes are shown in FIG. 5. See, e.g., GenBank Accession No. NP_049542 for AAV1 ; GenBank Accession No. NP_044927 for AAV4; GenBank Accession No.
  • GenBank Accession No. AAB95459 for AAV6 GenBank Accession No. YP_077178 for AAV7; GenBank Accession No. YP_077180 for AAV8; GenBank Accession No.
  • a heterologous peptide of from about 5 amino acids to about 20 amino acids in length is inserted into the GH loop of an AAV capsid, or replaces an equivalent number of consecutive amino acids in the GH loop of an AAV capsid.
  • the term "insertion peptide" is used below to describe both a peptide that is inserted into a parental AAV capsid and a peptide that replaces a segment of contiguous amino acids in the GH loop of an AAV capsid.
  • the insertion peptide has a length of from 5 amino acids to 20 amino acids.
  • the insertion peptide has a length of from 7 amino acids to 15 amino acids.
  • the insertion peptide has a length of from 9 amino acids to 15 amino acids. In some cases, the insertion peptide has a length of from 9 amino acids to 12 amino acids. The insertion peptide has a length of 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids. In some cases, the insertion peptide has a length of 7 amino acids. In some cases, the insertion peptide has a length of 8 amino acids. In some cases, the insertion peptide has a length of 9 amino acids.
  • the insertion peptide has a length of 10 amino acids. In some cases, the insertion peptide has a length of 11 amino acids. In some cases, the insertion peptide has a length of 12 amino acids. In some cases, the insertion peptide has a length of 13 amino acids. In some cases, the insertion peptide has a length of 14 amino acids. In some cases, the insertion peptide has a length of 15 amino acids.
  • the peptide insert is, in some cases, a peptide of Formula I:
  • a peptide of Formula I comprises the following amino acid sequence: (21)
  • a peptide of Formula I comprises the following amino acid sequence: (22) LANQEHVKNA (SEQ ID NO:2).
  • the peptide insert is, in some cases, a peptide of Formula II:
  • TX1X2X3X4X5X6X7X8GLX9 (SEQ ID NO: 137), where:
  • X 2 is V, E, P, G, D, M, A, or S;
  • X 3 is M, V, Y, H, G, S, or D;
  • X 4 is R, D, S, G, V, Y, T, H, or M;
  • Xs is S, L, G, T, Q, P, or A;
  • X 6 is T, A, S, M, D, Q, or H;
  • X 7 is N, G, S, L, M, P, G, or A
  • X 8 is S, G, D, N, A, I, P, or T
  • X 9 is S or N.
  • Peptide inserts of Formula II include, but are not limited to: (1) TGVMRSTNSGLN (SEQ ID NO: 6); (2) TGEVDLAGGGLS (SEQ ID NO: 7); (3) TSPYSGSSDGLS (SEQ ID NO: 8); (4) TGGHDSSLDGLS (SEQ ID NO: 9); (5) TGDGGTTMNGLS (SEQ ID NO: 98); (6)
  • TGGHGSAPDGLS (SEQ ID NO: 99); (7) TGMHVTMMAGLN (SEQ ID NO: 100); (8) TGASYLDNSGLS (SEQ ID NO: 101); (9) TVVSTQAGIGLS (SEQ ID NO: 135); (10) TGVMHSQASGLS (SEQ ID NO: 21); (11) TGDGSPAAPGLS (SEQ ID NO: 22); and (12) TGSDMAHGTGLS (SEQ ID NO: 23).
  • the peptide insert is (1)
  • the peptide insert is (3) TSPYSGSSDGLS (SEQ ID NO: 8). In some cases, the peptide insert is (4) TGGHDSSLDGLS (SEQ ID NO: 9). In some cases, the peptide insert is (5) TGDGGTTMNGLS (SEQ ID NO: 98). In some cases, the peptide insert is (6) TGGHGSAPDGLS (SEQ ID NO: 99). In some cases, the peptide insert is (7) TGMHVTMMAGLN (SEQ ID NO: 100). In some cases, the peptide insert is (8)
  • the peptide insert is (9)
  • TGVMHSQASGLS SEQ ID NO: 21.
  • the peptide insert is (11)
  • TGDGSPAAPGLS (SEQ ID NO: 22).
  • the peptide insert is (12)
  • the peptide insert is, in some cases, a peptide of Formula III:
  • Xi is V, E, P, G, D, M, A, or S;
  • X 2 is M, V, Y, H, G, S, or D;
  • X 3 is R, D, S, G, V, Y, T, H, or M;
  • X 4 is S, L, G, T, Q, P, or A;
  • Xs is T, A, S, M, D, Q, or H;
  • X 6 is N, G, S, L, M, P, G, or A;
  • X 7 is S, G, D, N, A, I, P, or T.
  • Peptide inserts of Formula III include, but are not limited to: (2) TGEVDLAGGGLS (SEQ ID NO: 1)
  • the peptide insert is, in some cases, a peptide of Formula IV:
  • X 2 is L, S,A, or G;
  • X 3 is D or V
  • X 4 is A, G, or P;
  • X5 is T or D
  • X 6 is R or Y
  • X 7 is D, T, or G
  • Xs is H, R, or T
  • X 9 is V or A
  • X 11 is T or A.
  • Peptide inserts of Formula IV include, but are not limited to: (13)
  • TGLDATRDHGLSPVTGT (SEQ ID NO: 24); (14) TGSDGTRDHGLSPVTWT (SEQ ID NO: 25); (15) NGAVADYTRGLSPATGT (SEQ ID NO: 26); and (16) TGGDPTRGTGLSPVTGA (SEQ ID NO: 27).
  • the peptide insert is (13) TGLDATRDHGLSPVTGT (SEQ ID NO: 24).
  • the peptide insert is (14) TGSDGTRDHGLSPVTWT (SEQ ID NO: 25).
  • the peptide insert is (15) NGAVADYTRGLSPATGT (SEQ ID NO: 26).
  • the peptide insert is (16) TGGDPTRGTGLSPVTGA (SEQ ID NO: 27).
  • the peptide insert is, in some cases, a peptide of Formula V:
  • Xi is L, S, A, or G
  • X 2 is A, G, or P;
  • X 3 is D, T, or G
  • X 4 is H, R, or T.
  • Peptide inserts of Formula V include, but are not limited to: (13)
  • TGLDATRDHGLSPVTGT SEQ ID NO: 24
  • TGSDGTRDHGLSPVTWT SEQ ID NO: 25
  • TGGDPTRGTGLSPVTGA SEQ ID NO: 27
  • the peptide insert is, in some cases, a peptide of Formula VI:
  • X 2 is N, G, or A;
  • X 3 is A, V, N, or D;
  • X 4 is P, I, or Q
  • Xs is A, P, or V;
  • X 6 is S, T, or G
  • X 7 is T or V
  • X 8 is E, L, A, or V;
  • X 9 is S, E, D, or V;
  • Xio is F, G, T, or C.
  • Peptides of Formula VI include, but are not limited to: (17) LQKNARPASTESVNFQ
  • LQRGNRPVTTADVNTQ (SEQ ID NO: 30); and (20) LQKADRQPGVVVVNCQ (SEQ ID NO: 31).
  • the peptide insert is (17) LQKNARPASTESVNFQ (SEQ ID NO: 28).
  • the peptide insert is (18) LQRGVRIPSVLEVNGQ (SEQ ID NO: 29).
  • the peptide insert is (19) LQRGNRPVTTADVNTQ (SEQ ID NO: 30).
  • the peptide insert is (20) LQKADRQPGVVVVNCQ (SEQ ID NO: 31).
  • any of the above -described peptide inserts can replace an equal number of contiguous amino acids in the GH loop of an AAV capsid polypeptide.
  • a peptide of Formula VI a peptide of Formula VI:
  • X 2 is N, G, or A
  • X 3 is A, V, N, or D;
  • X 4 is P, I, or Q
  • Xs is A, P, or V;
  • X 6 is S, T, or G
  • X 7 is T or V
  • X 8 is E, L, A, or V;
  • X 9 is S, E, D, or V;
  • Xio is F, G, T, or C
  • an "insert peptide” replaces an endogenous peptide (e.g., a contiguous stretch of from 5 amino acids to 20 amino acids) present in in the GH loop of an AAV capsid polypeptide, resulting in a variant AAV capsid comprising a heterologous peptide in the GH loop.
  • the "insert peptide” replaces an endogenous contiguous stretch of amino acids of the same length as the insert peptide.
  • an endogenous contiguous stretch of 16 amino acids is replaced by the insert peptide.
  • Peptides of Formula VI include, but are not limited to: (17) LQKNARPASTESVNFQ
  • LQRGNRPVTTADVNTQ (SEQ ID NO:30); and (20) LQKADRQPGVVVVNCQ (SEQ ID NO: 31).
  • the peptide that replaces an endogenous amino acid sequence in the GH loop of an AAV capsid is (17) LQKNARPASTESVNFQ (SEQ ID NO: 28).
  • the peptide insert is (18) LQRGVRIPSVLEVNGQ (SEQ ID NO: 29).
  • the peptide that replaces an endogenous amino acid sequence in the GH loop of an AAV capsid is (19)
  • the peptide that replaces an endogenous amino acid sequence in the GH loop of an AAV capsid is (20)
  • a peptide insert of any one of Formulas I-VI further includes one or two linker amino acids at the N-terminus of the peptide and/or one or more amino acids at the C- terminus of the peptide.
  • a peptide insert comprises: Thr-Gly- [peptide of any one of Formulas I-VI]-Gly-Leu-Ser (SEQ ID NO: 142).
  • a peptide insert comprises: Leu- Ala- [peptide of any one of Formulas I-VI]-Ala (SEQ ID NO: 143).
  • a peptide insert comprises: Leu-Gln- [peptide of any one of Formulas I-VI] -Gin.
  • a peptide insert does not include any linker amino acids.
  • a subject rAAV virion capsid does not include any other amino acid substitutions, insertions, or deletions, other than an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to a corresponding parental AAV capsid protein.
  • a subject rAAV virion capsid includes from 1 to about 25 amino acid insertions, deletions, or
  • substitutions compared to the parental AAV capsid protein, in addition to an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to a corresponding parental AAV capsid protein.
  • amino acids e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids
  • a subject rAAV virion capsid includes from 1 to about 5, from about 5 to about 10, from about 10 to about 15, from about 15 to about 20, or from about 20 to about 25 amino acid insertions, deletions, or substitutions, compared to the parental AAV capsid protein, in addition to an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to a corresponding parental AAV capsid protein.
  • the deletion of one or more amino acids compared to the parental AAV capsid protein occurs at the site of peptide insertion.
  • a variant AAV capsid polypeptide of the present disclosure does not include one, two, three, or four, of the following amino acid substitutions: Y273F, Y444F, Y500F, and Y730F.
  • a variant AAV capsid polypeptide of the present disclosure comprises, in addition to an insertion peptide as described above, one, two, three, or four, of the following amino acid substitutions: Y273F, Y444F, Y500F, and Y730F.
  • a variant AAV capsid polypeptide of the present disclosure is a chimeric capsid, e.g., the capsid comprises a portion of an AAV capsid of a first AAV serotype and a portion of an AAV capsid of a second serotype; and comprises an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to a corresponding parental AAV capsid protein.
  • the capsid comprises a portion of an AAV capsid of a first AAV serotype and a portion of an AAV capsid of a second serotype; and comprises an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g.,
  • the present disclosure provides a recombinant AAV (rAAV) virion comprising: i) a variant AAV capsid polypeptide of the present disclosure; and ii) a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous polypeptide (i.e., a non-AAV polypeptide).
  • rAAV recombinant AAV
  • an rAAV virion of the present disclosure comprises a capsid protein comprising an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%, amino acid sequence identity to the amino acid sequence provided in FIG. 4; and an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to a corresponding parental AAV capsid protein.
  • a subject rAAV virion comprises a capsid protein comprising an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%, amino acid sequence identity to the amino acid sequence provided in FIG. 4; and an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) between amino acids 587 and 588 relative to the amino acid sequence depicted in FIG. 4, or at a corresponding site relative to a corresponding parental AAV capsid protein.
  • an rAAV virion of the present disclosure comprises a capsid protein comprising an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%, amino acid sequence identity to the amino acid sequence provided in FIG. 4; and an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) in the GH loop or loop IV relative to a corresponding parental AAV capsid protein.
  • a subject rAAV virion comprises a capsid protein comprising an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%, amino acid sequence identity to the amino acid sequence provided in FIG. 4; and an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) between amino acids 585 and 598 relative to the amino acid sequence depicted in FIG. 4, or at a corresponding site relative to a corresponding parental AAV capsid protein.
  • a subject rAAV virion comprises a capsid protein that includes a
  • GH loop comprising an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to an amino acid sequence set forth in FIG. 5, and comprising an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) between the bolded and underlined amino acids.
  • a subject rAAV virion comprises a capsid protein comprising an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%, amino acid sequence identity to any one of the amino acid sequences provided in FIG. 6A-6C; and an insertion of from about 5 amino acids to about 20 amino acids (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids; e.g., 9 amino acids, 10 amino acids, 11 amino acids, or 12 amino acids) between amino acids 587 and 588 of AAV2, or at a corresponding site relative to another AAV genotype.
  • the corresponding insertion site is a site as indicated by bold text and underlining in FIG. 6B.
  • An rAAV virion of the present disclosure exhibits at least 5-fold, at least 10-fold, at least
  • Whether a given rAAV virion exhibits increased infectivity of a retinal cell can be determined by detecting expression in a retinal cell of a heterologous gene product encoded by the rAAV virion, following intravitreal administration of the rAAV virion.
  • an rAAV virion of the present disclosure that comprises: a) a variant capsid of the present disclosure comprising a peptide insert or a peptide replacement, as described above; and b) a heterologous nucleotide sequence encoding a heterologous gene product, when administered intravitreally, results in a level of the heterologous gene product in a retinal cell, that is at least 2- fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50- fold, or more than 50-fold, greater than the level of the gene product in the retinal cell that results when a control rAAV virion that comprises: a) a control AAV capsid that does not comprises the peptide insert or the peptide replacement; and b) heterologous nucleotide sequence encoding the heterologous gene product is administered intravitreally.
  • Therapeutic effects can include, e.g., a) a decrease in the rate of loss of visual function, e.g. visual field, visual acuity; b) an improvement in visual function, e.g. an improvement in visual field or visual acuity; c) a decrease in sensitivity to light, i.e. photophobia; a decrease in nystagmus; etc.
  • an rAAV virion of the present disclosure that comprises: a) a variant capsid of the present disclosure comprising a peptide insert or a peptide replacement, as described above; and b) a heterologous nucleotide sequence encoding a heterologous therapeutic gene product, when administered intravitreally, results in a therapeutic effect of the therapeutic gene product in a retinal cell, that is at least 2-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50- fold, greater than the therapeutic effect in the retinal cell that results when a control rAAV virion that comprises: a) a control AAV capsid that does not comprises the peptide insert or the peptide replacement; and b) heterologous nucleotide sequence encoding the heterologous therapeutic gene product is administered intravitreally.
  • Tests for visual function are known in the art; and any such test can be used to determine whether an
  • An rAAV virion of the present disclosure exhibits at least 5-fold, at least 10-fold, at least
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15- fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a retinal cell, when administered via intra vitreal injection, compared to the infectivity of the retinal cell by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a photoreceptor (rod or cone) cell, compared to the infectivity of the photoreceptor cell by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a photoreceptor (rod or cone) cell, when administered via intravitreal injection, compared to the infectivity of the photoreceptor cell by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of an RGC, compared to the infectivity of the RGC by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of an RGC, when administered via intravitreal injection, compared to the infectivity of the RGC by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of an RPE cell, compared to the infectivity of the RPE cell by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of an RPE cell, when administered via intravitreal injection, compared to the infectivity of the RPE cell by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a Muller cell, compared to the infectivity of the Muller cell by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a Muller cell, when administered via intravitreal injection, compared to the infectivity of the Muller cell by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a bipolar cell, compared to the infectivity of the bipolar cell by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a bipolar cell, when administered via intravitreal injection, compared to the infectivity of the bipolar cell by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of an amacrine cell, compared to the infectivity of the amacrine cell by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of an amacrine cell, when administered via intravitreal injection, compared to the infectivity of the amacrine cell by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a horizontal cell, compared to the infectivity of the horizontal cell by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a horizontal cell, when administered via intravitreal injection, compared to the infectivity of the horizontal cell by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a retinal astrocyte, compared to the infectivity of the retinal astrocyte by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a retinal astrocyte, when administered via intravitreal injection, compared to the infectivity of the retinal astrocyte by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15- fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased ability to cross extracellular matrix (ECM) of the retina, compared to the ability of an AAV virion comprising the corresponding parental AAV capsid protein to cross the ECM of the retina.
  • ECM extracellular matrix
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15- fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased ability, when administered via intravitreal injection, to cross extracellular matrix (ECM) of the retina, compared to the ability of an AAV virion comprising the corresponding parental AAV capsid protein to cross the ECM of the retina when administered via intravitreal injection.
  • ECM extracellular matrix
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15- fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased ability to cross the internal limiting membrane (ILM), compared to the ability of an AAV virion comprising the corresponding parental AAV capsid protein to cross the ILM.
  • ILM internal limiting membrane
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15- fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased ability, when administered via intravitreal injection, to cross the ILM, compared to the ability of an AAV virion comprising the corresponding parental AAV capsid protein to cross the ILM when administered via intravitreal injection.
  • a subject rAAV virion can cross the ILM, and can also traverse cell layers, including
  • Muller cells, amacrine cells, etc. to reach the photoreceptor cells and or RPE cells.
  • a subject rAAV virion when administered via intravitreal injection, can cross the ILM, and can also traverse cell layers, including Muller cells, amacrine cells, etc., to reach the photoreceptor cells and or RPE cells.
  • a subject rAAV virion exhibits at least 5-fold, at least 10-fold, at least 15- fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased localization to one or more of the inner nuclear layer, the outer nuclear layer, the photoreceptor layer, the ganglion cell layer, and the retinal pigment epithelium, compared to the extent of localization to the inner nuclear layer, the outer nuclear layer, the photoreceptor layer, the ganglion cell layer, or the retinal pigment epithelium, by an AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion when injected intravitreally, exhibits at least 5- fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased localization past the ILM, compared to the extent of localization past the ILM by an intravitreally injected control AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion when injected intravitreally, exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased localization to the retinal pigment epithelium (RPE), compared to the extent of localization to the RPE layer by an intravitreally injected control AAV virion comprising the corresponding parental AAV capsid protein.
  • RPE retinal pigment epithelium
  • a subject rAAV virion when injected intravitreally, exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased localization to the photoreceptor (PR) layer, compared to the extent of localization to the PR layer by an intravitreally injected control AAV virion comprising the corresponding parental AAV capsid protein.
  • PR photoreceptor
  • a subject rAAV virion when injected intravitreally, exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased localization to the inner nuclear layer, compared to the extent of localization to the inner nuclear layer by an intravitreally injected control AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion when injected intravitreally, exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased localization to the outer nuclear layer, compared to the extent of localization to the outer nuclear layer by an intravitreally injected control AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion when injected intravitreally, exhibits at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased localization to the ganglion cell layer, compared to the extent of localization to the ganglion cell layer by an intravitreally injected control AAV virion comprising the corresponding parental AAV capsid protein.
  • a subject rAAV virion selectively infects a retinal cell, e.g., a subject rAAV virion infects a retinal cell with 10-fold, 15-fold, 20-fold, 25-fold, 50-fold, or more than 50-fold, specificity than a non-retinal cell, e.g., a cell outside the eye.
  • a subject rAAV virion selectively infects a retinal cell, e.g., a subject rAAV virion infects a photoreceptor cell with 10-fold, 15-fold, 20-fold, 25-fold, 50-fold, or more than 50-fold, specificity than a non-retinal cell, e.g., a cell outside the eye.
  • a retinal cell e.g., a subject rAAV virion infects a photoreceptor cell with 10-fold, 15-fold, 20-fold, 25-fold, 50-fold, or more than 50-fold, specificity than a non-retinal cell, e.g., a cell outside the eye.
  • a subject rAAV virion selectively infects a photoreceptor cell, e.g., a subject rAAV virion infects a photoreceptor cell with 10-fold, 15-fold, 20-fold, 25-fold, 50-fold, or more than 50-fold, specificity than a non-photoreceptor cell present in the eye, e.g., a retinal ganglion cell, a Muller cell, etc.
  • a subject rAAV virion exhibits at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more than 50-fold, increased infectivity of a photoreceptor cell, when administered via intravitreal injection, compared to the infectivity of the photoreceptor cell by an AAV virion comprising the corresponding parental AAV capsid protein, when administered via intravitreal injection.
  • An rAAV virion of the present disclosure comprises a heterologous nucleic acid
  • nucleotide sequence encoding one or more gene products (one or more
  • an rAAV virion of the present disclosure comprises a heterologous nucleotide sequence encoding both a heterologous nucleic acid gene product and a heterologous polypeptide gene product. Where the gene product is an RNA, in some cases, the RNA gene product encodes a polypeptide. Where the gene product is an RNA, in some cases, the RNA gene product does not encode a polypeptide. In some cases, an rAAV virion of the present disclosure comprises a single heterologous nucleic acid comprising a nucleotide sequence encoding a single heterologous gene product.
  • an rAAV virion of the present disclosure comprises a single heterologous nucleic acid comprising a nucleotide sequence encoding two heterologous gene products.
  • the single heterologous nucleic acid encodes two heterologous gene products
  • nucleotide sequences encoding the two heterologous gene products are operably linked to the same promoter.
  • nucleotide sequences encoding the two heterologous gene products are operably linked to two different promoters.
  • an rAAV virion of the present disclosure comprises a single heterologous nucleic acid comprising a nucleotide sequence encoding three heterologous gene products.
  • the single heterologous nucleic acid encodes three heterologous gene products, in some cases, nucleotide sequences encoding the three heterologous gene products are operably linked to the same promoter.
  • nucleotide sequences encoding the three heterologous gene products are operably linked to the same promoter.
  • nucleotide sequences encoding the three heterologous gene products in some cases, nucleotide sequences encoding the three
  • heterologous gene products are operably linked to two or three different promoters.
  • an rAAV virion of the present disclosure comprises two heterologous nucleic acids, each comprising a nucleotide sequence encoding a heterologous gene product.
  • the gene product is a polypeptide -encoding RNA.
  • the gene product is an interfering RNA.
  • the gene product is an aptamer.
  • the gene product is a polypeptide.
  • the gene product is a therapeutic polypeptide, e.g., a polypeptide that provides clinical benefit.
  • the gene product is a site- specific nuclease that provide for site-specific knock-down of gene function.
  • the gene product is an RNA-guided endonuclease that provides for modification of a target nucleic acid.
  • the gene products are: i) an RNA-guided endonuclease that provides for modification of a target nucleic acid; and ii) a guide RNA that comprises a first segment that binds to a target sequence in a target nucleic acid and a second segment that binds to the RNA-guided endonuclease.
  • the gene products are: i) an RNA-guided endonuclease that provides for modification of a target nucleic acid; ii) a first guide RNA that comprises a first segment that binds to a first target sequence in a target nucleic acid and a second segment that binds to the RNA-guided endonuclease; and iii) a first guide RNA that comprises a first segment that binds to a second target sequence in the target nucleic acid and a second segment that binds to the RNA-guided endonuclease.
  • RNAi interfering RNA
  • suitable RNAi include RNAi that decrease the level of an apoptotic or angiogenic factor in a cell.
  • an RNAi can be an shRNA or siRNA that reduces the level of a gene product that induces or promotes apoptosis in a cell.
  • Genes whose gene products induce or promote apoptosis are referred to herein as "pro- apoptotic genes" and the products of those genes (mRNA; protein) are referred to as "pro- apoptotic gene products.”
  • Pro-apoptotic gene products include, e.g., Bax, Bid, Bak, and Bad gene products. See, e.g., U.S. Patent No. 7,846,730.
  • Interfering RNAs could also be against an angiogenic product, for example vascular endothelial growth factor (VEGF) (e.g., Cand5; see, e.g., U.S. Patent Publication No.
  • VEGF vascular endothelial growth factor
  • Cand5 see, e.g., U.S. Patent Publication No.
  • VEGF receptor-1 e.g., Sirna-027; see, e.g., Kaiser et al. (2010) Am. J.
  • exemplary aptamers of interest include an
  • a VEGF aptamer against VEGF. See, e.g., Ng et al. (2006) Nat. Rev. Drug Discovery 5:123; and Lee et al. (2005) Proc. Natl. Acad. Sci. USA 102: 18902.
  • a VEGF aptamer can comprise the nucleotide sequence 5 '-cgcaaucagugaaugcuuauacauccg-3' (SEQ ID NO:3).
  • PDGF platelet-derived growth factor
  • E10030 see, e.g., Ni and Hui (2009) Ophthalmologica 223:401; and Akiyama et al. (2006) /. Cell Physiol. 207:407).
  • the gene product is a polypeptide
  • the polypeptide is a polypeptide that enhances function of a retinal cell, e.g., the function of a rod or cone photoreceptor cell, a retinal ganglion cell, a Muller cell, a bipolar cell, an amacrine cell, a horizontal cell, or a retinal pigment epithelial cell.
  • polypeptides include neuroprotective polypeptides (e.g., glial cell derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), neurotrophin-4 (NT4), nerve growth factor (NGF), and neurturin (NTN)); anti-angiogenic polypeptides (e.g., a soluble VEGF receptor; a VEGF-binding antibody; a VEGF-binding antibody fragment (e.g., a single chain anti-VEGF antibody); endostatin; tumstatin; angiostatin; a soluble Fit polypeptide (Lai et al. (2005) Mol. Ther.
  • neuroprotective polypeptides e.g., glial cell derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), neurotrophin-4 (NT4), nerve growth factor (NGF), and neurturin (NTN)
  • anti-angiogenic polypeptides e.g., a soluble
  • an Fc fusion protein comprising a soluble Fit polypeptide (see, e.g., Pechan et al. (2009) Gene Ther. 16:10); pigment epithelium-derived factor (PEDF); a soluble Tie-2 receptor; etc.); tissue inhibitor of metalloproteinases-3 (TIMP-3); a light- responsive opsin, e.g., a rhodopsin; anti-apoptotic polypeptides (e.g., Bcl-2, Bcl-Xl; XIAP); and the like.
  • a soluble Fit polypeptide see, e.g., Pechan et al. (2009) Gene Ther. 16:10
  • PEDF pigment epithelium-derived factor
  • TMP-3 tissue inhibitor of metalloproteinases-3
  • a light- responsive opsin e.g., a rhodopsin
  • anti-apoptotic polypeptides e.g., Bcl-2, Bc
  • Suitable polypeptides include, but are not limited to, glial derived neurotrophic factor (GDNF); fibroblast growth factor; fibroblast growth factor 2; neurturin (NTN); ciliary neurotrophic factor (CNTF); nerve growth factor (NGF); neurotrophin-4 (NT4); brain derived neurotrophic factor (BDNF; e.g., a polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to a contiguous stretch of from about 200 amino acids to 247 amino acids of the amino acid sequence depicted in Figure 7B (SEQ ID NO: 11)); epidermal growth factor; rhodopsin; X-linked inhibitor of apoptosis; and Sonic hedgehog.
  • GDNF glial derived neurotrophic factor
  • NTN ciliary neurotrophic factor
  • NTF nerve growth factor
  • NT4 neurotrophin-4
  • BDNF brain derived
  • Suitable light-responsive opsins include, e.g., a light-responsive opsin as described in
  • Patent Publication No. 2001/0086421 U.S. Patent Publication No. 2010/0015095; U.S. Patent Publication No. 2016/0002302; U.S. Patent Publication No. 2013/0347137; U.S. Patent
  • Suitable polypeptides include light-gated ion channel polypeptides. See, e.g., Gaub et al.
  • a suitable polypeptide is a light- gated ionotropic glutamate receptor (LiGluR).
  • LiGluR light- gated ionotropic glutamate receptor
  • LiGluR comprises a L439C substitution; see, Caporale et al. (2011) Mol Ther. 19: 1212— 1219; Volgraf et al. (2006) Nat Chem Biol. 2:47-52; and Gorostiza et al. (2007) Proc Natl Acad Sci USA. 104: 10865-10870.
  • Photoisomerizable compounds include, e.g., maleimide- azobenzene-glutamate 0 with peak efficiency at 460 nm (MAGO460).
  • MAGO460 has the following structure:
  • Suitable polypeptides also include retinoschisin (e.g., a polypeptide comprising an retinoschisin
  • polypeptides include, e.g., retinitis pigmentosa GTPase regulator (RPGR)- interacting protein-1 (see, e.g., GenBank Accession Nos.
  • RPGR retinitis pigmentosa GTPase regulator
  • Q96KN7, Q9EPQ2, and Q9GLM3 e.g., a polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to a contiguous stretch of from about 1150 amino acids to about 1200 amino acids, or from about 1200 amino acids to 1286 amino acids, of the amino acid sequence depicted in FIG. 7F (SEQ ID NO: 15); peripherin-2 (Prph2) (see, e.g., GenBank Accession No.
  • NP_000313 e.g., a polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to a contiguous stretch of from about 300 amino acids to 346 amino acids of the amino acid sequence depicted in FIG. 7D (SEQ ID NO: 13); and Travis et al. (1991) Genomics 10:733); peripherin (e.g., a polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to a contiguous stretch of from about 400 amino acids to about 470 amino acids of the amino acid sequence depicted in FIG.
  • peripherin e.g., a polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to a contiguous stretch of
  • a retinal pigment epithelium-specific protein e.g., a polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to a contiguous stretch of from about 200 amino acids to 247 amino acids of the amino acid sequence depicted in FIG. 7C (SEQ ID NO: 12)) (see, e.g., GenBank AAC39660; and Morimura et al. (1998) Proc. Natl. Acad. Sci.
  • RPE65 retinal pigment epithelium-specific protein
  • rod-derived cone viability factor e.g., a polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence depicted in any one of FIG. 7H, 71, and 7J
  • Rab escort protein 1 REP1
  • FIG. 7H, 71, and 7J Rab escort protein 1
  • retinitis pigmentosa GTPase regulator e.g., a polypeptide comprising an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence depicted in one of FIG. 7S-7V; and the like.
  • RPGR retinitis pigmentosa GTPase regulator
  • a suitable RPGR polypeptide comprises an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence depicted in FIG. 7S.
  • a suitable RPGR polypeptide comprises an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence depicted in FIG. 7T.
  • a suitable RPGR polypeptide comprises an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence depicted in FIG. 7U.
  • a suitable RPGR polypeptide comprises an amino acid sequence having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence depicted in FIG. 7V.
  • Suitable polypeptides also include: CHM (choroideremia (Rab escort protein 1
  • REP1 a polypeptide that, when defective or missing, causes choroideremia (see, e.g., Donnelly et al. (1994) Hum. Mol. Genet. 3: 1017; and van Bokhoven et al. (1994) Hum. Mol. Genet. 3: 1041); and Crumbs homolog 1 (CRB 1), a polypeptide that, when defective or missing, causes Leber congenital amaurosis and retinitis pigmentosa (see, e.g., den Hollander et al. (1999) Nat. Genet. 23:217; and GenBank Accession No. CAM23328).
  • CRB 1 Crumbs homolog 1
  • a suitable REP1 polypeptide can comprise an amino acid having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence set depicted in FIG. 7G.
  • Suitable polypeptides include Rod cGMP-specific 3' ,5'-cyclic phosphodiesterase subunit alpha (PDE6a), Rod cGMP-specific 3 ',5 '-cyclic phosphodiesterase subunit beta isoform 1 ( ⁇ 6 ⁇ isoform 1), Rod cGMP-specific 3 ',5 '-cyclic phosphodiesterase subunit beta isoform 2 ( ⁇ 6 ⁇ isoform 2), Rod cGMP-specific 3 ',5 '-cyclic phosphodiesterase subunit beta isoform 3 ( ⁇ 6 ⁇ isoform 3).
  • a suitable PDE6a polypeptide can comprise an amino acid having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence set depicted in FIG. 7K.
  • a suitable ⁇ 6 ⁇ 6 isoform 1 polypeptide can comprise an amino acid having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence set depicted in FIG. 7L.
  • a suitable ⁇ 6 ⁇ 6 isoform 2 polypeptide can comprise an amino acid having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence set depicted in FIG. 7M.
  • a suitable ⁇ 6 ⁇ 6 isoform 3 polypeptide can comprise an amino acid having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence set depicted in FIG. 7N.
  • Suitable polypeptides also include polypeptides that, when defective or missing, lead to achromotopsia, where such polypeptides include, e.g., cone photoreceptor cGMP-gated channel subunit alpha (CNGA3) (see, e.g., GenBank Accession No. NP_001289; and Booij et al. (2011) Ophthalmology 118: 160-167); cone photoreceptor cGMP-gated cation channel beta-subunit (CNGB3) (see, e.g., Kohl et al.(2005) Eur J Hum Genet.
  • CNGA3 cone photoreceptor cGMP-gated channel subunit alpha
  • CNGB3 cone photoreceptor cGMP-gated cation channel beta-subunit
  • G protein guanine nucleotide binding protein
  • GNAT2 alpha transducing activity polypeptide 2
  • ACHM5 alpha transducing activity polypeptide 5
  • polypeptides that, when defective or lacking, lead to various forms of color blindness e.g., L-opsin, M-opsin, and S-opsin.
  • a suitable CNGA3 also known as ACHM2 isoform 1 polypeptide can comprise an amino acid having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence set depicted in FIG. 70.
  • a suitable CNGA3 also known as ACHM2 isoform 2 polypeptide can comprise an amino acid having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence set depicted in FIG. 7P.
  • CNGB3 also known as ACHM3 polypeptide
  • GNAT2 also known as ACHM4
  • GNAT2 can comprise an amino acid having at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100%, amino acid sequence identity to the amino acid sequence set depicted in FIG. 7R.
  • a gene product of interest is a site-specific endonuclease that provide for site-specific knock-down of gene function, e.g., where the endonuclease knocks out an allele associated with a retinal disease.
  • a site-specific endonuclease can be targeted to the defective allele and knock out the defective allele.
  • a site-specific endonuclease is an RNA-guided endonuclease.
  • a site-specific nuclease can also be used to stimulate homologous recombination with a donor DNA that encodes a functional copy of the protein encoded by the defective allele.
  • a subject rAAV virion can be used to deliver both a site-specific endonuclease that knocks out a defective allele, and can be used to deliver a functional copy of the defective allele, resulting in repair of the defective allele, thereby providing for production of a functional retinal protein (e.g., functional retinoschisin, functional RPE65, functional peripherin, etc.). See, e.g., Li et al.
  • a subject rAAV virion comprises a heterologous nucleotide sequence that encodes a site-specific endonuclease; and a heterologous nucleotide sequence that encodes a functional copy of a defective allele, where the functional copy encodes a functional retinal protein.
  • Functional retinal proteins include, e.g., retinoschisin, RPE65, retinitis pigmentosa GTPase regulator (RGPR)-interacting protein- 1, peripherin, peripherin-2, RdCVF, and the like.
  • retinoschisin RPE65
  • RGPR retinitis pigmentosa GTPase regulator
  • Site-specific endonucleases that are suitable for use include, e.g., zinc finger nucleases
  • ZFNs ZFNs
  • meganucleases meganucleases
  • transcription activator-like effector nucleases TALENs
  • site-specific endonucleases can be engineered to cut specific locations within a genome, and non-homologous end joining can then repair the break while inserting or deleting several nucleotides.
  • site-specific endonucleases also referred to as "INDELs” then throw the protein out of frame and effectively knock out the gene. See, e.g., U.S. Patent Publication No. 2011/0301073.
  • Suitable site-specific endonucleases include engineered meganucleases and re- engineered homing endonucleases.
  • Suitable endonucleases include an I-Tevl nuclease.
  • Suitable meganucleases include I-Scel (see, e.g., Bellaiche et al. (1999) Genetics 152: 1037); and I-Crel (see, e.g., Heath et al. (1997) Nature Structural Biology 4:468).
  • the gene product is an RNA-guided endonuclease.
  • the gene product is an RNA comprising a nucleotide sequence encoding an RNA-guided endonuclease.
  • the gene product is a guide RNA, e.g., a single -guide RNA.
  • the gene products are: 1) a guide RNA; and 2) an RNA-guided endonuclease.
  • the guide RNA can comprise: a) a protein-binding region that binds to the RNA-guided
  • RNA-guided endonuclease is also referred to herein as a "genome editing nuclease.”
  • Suitable genome editing nucleases are CRISPR/Cas endonucleases (e.g., class 2 CRISPR/Cas endonucleases such as a type II, type V, or type VI CRISPR/Cas endonucleases).
  • a suitable genome editing nuclease is a CRISPR/Cas endonuclease (e.g., a class 2 CRISPR/Cas endonuclease such as a type II, type V, or type VI CRISPR/Cas endonuclease).
  • a genome targeting composition includes a class 2 CRISPR/Cas endonuclease.
  • a genome targeting composition includes a class 2 type II CRISPR/Cas
  • a genome targeting composition includes a class 2 type V CRISPR/Cas endonuclease (e.g., a Cpfl protein, a C2cl protein, or a C2c3 protein).
  • a genome targeting composition includes a class 2 type VI CRISPR/Cas endonuclease (e.g., a C2c2 protein; also referred to as a "Casl3a" protein).
  • a CasX protein is also suitable for use.
  • a genome editing nuclease is a fusion protein that is fused to a
  • heterologous polypeptide also referred to as a "fusion partner"
  • a genome editing nuclease is fused to an amino acid sequence (a fusion partner) that provides for subcellular localization, i.e., the fusion partner is a subcellular localization sequence (e.g., one or more nuclear localization signals (NLSs) for targeting to the nucleus, two or more NLSs, three or more NLSs, etc.).
  • a fusion partner e.g., one or more nuclear localization signals (NLSs) for targeting to the nucleus, two or more NLSs, three or more NLSs, etc.
  • the genome-editing endonuclease is a Type II CRISPR/Cas endonuclease.
  • the genome-editing endonuclease is a Cas9 polypeptide.
  • the Cas9 protein is guided to a target site (e.g., stabilized at a target site) within a target nucleic acid sequence (e.g., a chromosomal sequence or an extrachromosomal sequence, e.g., an episomal sequence, a minicircle sequence, a mitochondrial sequence, a chloroplast sequence, etc.) by virtue of its association with the protein-binding segment of the Cas9 guide RNA.
  • a target nucleic acid sequence e.g., a chromosomal sequence or an extrachromosomal sequence, e.g., an episomal sequence, a minicircle sequence, a mitochondrial sequence, a chloroplast sequence, etc.
  • a Cas9 polypeptide comprises an amino acid sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or more than 99%, amino acid sequence identity to the Streptococcus pyogenes Cas9 depicted in FIG. 3A.
  • the Cas9 polypeptide used in a composition or method of the present disclosure is a Staphylococcus aureus Cas9 (saCas9) polypeptide.
  • the saCas9 polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the saCas9 amino acid sequence depicted in FIG. 3B.
  • a suitable Cas9 polypeptide is a high-fidelity (HF) Cas9 polypeptide.
  • amino acids N497, R661, Q695, and Q926 of the amino acid sequence depicted in FIG. 3A are substituted, e.g., with alanine.
  • an HF Cas9 polypeptide can comprise an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence depicted in FIG. 3A, where amino acids N497, R661, Q695, and Q926 are substituted, e.g., with alanine.
  • a suitable Cas9 polypeptide exhibits altered PAM specificity. See, e.g.,
  • the genome-editing endonuclease is a type V CRISPR/Cas endonuclease.
  • a type V CRISPR/Cas endonuclease is a Cpfl protein.
  • a Cpf 1 protein comprises an amino acid sequence having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 90%, or 100%, amino acid sequence identity to the Cpfl amino acid sequence depicted in FIG. 3C.
  • the genome-editing endonuclease is a CasX or a CasY polypeptide.
  • CasX and CasY polypeptides are described in Burstein et al. (2017) Nature 542:237 '.
  • RNA-guided endonuclease with reduced enzymatic activity.
  • RNA-guided endonuclease is referred to as a "dead” RNA-guided endonuclease; for example, a Cas9 polypeptide that comprises certain amino acid substitutions such that it exhibits substantially no endonuclease activity, but such that it still binds to a target nucleic acid when complexed with a guide RNA, is referred to as a “dead” Cas9 or "dCas9.”
  • a "dead” Cas9 protein has a reduced ability to cleave both the complementary and the non- complementary strands of a double stranded target nucleic acid.
  • a "nuclease defective" Cas9 lacks a functioning RuvC domain (i.e., does not cleave the non-complementary strand of a double stranded target DNA) and lacks a functioning HNH domain (i.e., does not cleave the complementary strand of a double stranded target DNA).
  • the nuclease defective Cas9 protein harbors mutations at amino acid positions corresponding to residues D10 and H840 (e.g., D10A and H840A) of SEQ ID NO: 15 (or the corresponding residues of a homolog of Cas9) such that the polypeptide has a reduced ability to cleave (e.g., does not cleave) both the complementary and the non-complementary strands of a target nucleic acid.
  • Such a Cas9 protein has a reduced ability to cleave a target nucleic acid (e.g., a single stranded or double stranded target nucleic acid) but retains the ability to bind a target nucleic acid.
  • a Cas9 protein that cannot cleave target nucleic acid e.g., due to one or more mutations, e.g., in the catalytic domains of the RuvC and HNH domains
  • a nuclease defective Cas9 e.g., due to one or more mutations, e.g., in the catalytic domains of the RuvC and HNH domains
  • Other residues can be mutated to achieve the above effects (i.e. inactivate one or the other nuclease portions).
  • residues DIO, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or A987 of Streptococcus pyogenes Cas9 can be altered (i.e., substituted).
  • two or more of DIO, E762, H840, N854, N863, and D986 of Streptococcus pyogenes Cas9 are substituted.
  • DIO and N863 of Streptococcus pyogenes Cas9 are substituted with Ala.
  • mutations other than alanine substitutions are suitable.
  • the genome-editing endonuclease is an RNA-guided endonuclease (and it corresponding guide RNA) known as Cas9-synergistic activation mediator (Cas9-SAM).
  • Cas9-SAM Cas9-synergistic activation mediator
  • RNA-guided endonuclease (e.g., Cas9) of the Cas9-SAM system is a "dead" Cas9 fused to a transcriptional activation domain (wherein suitable transcriptional activation domains include, e.g., VP64, p65, MyoDl, HSFl, RTA, and SET7/9) or a transcriptional repressor domain (where suitable transcriptional repressor domains include, e.g., a KRAB domain, a NuE domain, an NcoR domain, a SID domain, and a SID4X domain).
  • the guide RNA of the Cas9-SAM system comprises a loop that binds an adapter protein fused to a transcriptional activator domain (e.g., VP64, p65, MyoDl, HSFl, RTA, or SET7/9) or a transcriptional repressor domain (e.g., a KRAB domain, a NuE domain, an NcoR domain, a SID domain, or a SID4X domain).
  • a transcriptional activator domain e.g., VP64, p65, MyoDl, HSFl, RTA, or SET7/9
  • a transcriptional repressor domain e.g., a KRAB domain, a NuE domain, an NcoR domain, a SID domain, or a SID4X domain.
  • the guide RNA is a single -guide RNA comprising an MS2 RNA aptamer inserted into one or two loops of the sgRNA;
  • the dCas9 is a fusion polypeptide comprising dCas9 fused to VP64;
  • the adaptor/functional protein is a fusion polypeptide comprising: i) MS2; ii) p65; and iii) HSFl. See, e.g., U.S. Patent Publication No. 2016/0355797.
  • a chimeric polypeptide comprising: a) a dead RNA-guided
  • heterologous fusion polypeptide examples include a polypeptide having, e.g., methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, DNA cleavage activity, DNA integration activity, or nucleic acid binding activity.
  • a nucleic acid that binds to a class 2 CRISPR/Cas endonuclease e.g., a Cas9 protein; a type V or type VI CRISPR/Cas protein; a Cpfl protein; etc.
  • a guide RNA or "CRISPR/Cas guide nucleic acid” or "CRISPR/Cas guide RNA.”
  • a guide RNA provides target specificity to the complex (the RNP complex) by including a targeting segment, which includes a guide sequence (also referred to herein as a targeting sequence), which is a nucleotide sequence that is complementary to a sequence of a target nucleic acid.
  • a guide RNA includes two separate nucleic acid molecules: an "activator” and a “targeter” and is referred to herein as a “dual guide RNA", a “double-molecule guide RNA”, a “two-molecule guide RNA”, or a “dgRNA.”
  • the guide RNA is one molecule (e.g., for some class 2 CRISPR/Cas proteins, the corresponding guide RNA is a single molecule; and in some cases, an activator and targeter are covalently linked to one another, e.g., via intervening nucleotides), and the guide RNA is referred to as a "single guide RNA", a “single-molecule guide RNA,” a “one-molecule guide RNA”, or simply "sgRNA.”
  • the gene product is an RNA-guided endonuclease, or is both an RNA-guided endonuclease and a guide RNA
  • the gene product can modify a target nucleic acid.
  • a target nucleic acid comprises a deleterious mutation in a defective allele (e.g., a deleterious mutation in a retinal cell target nucleic acid)
  • endonuclease/guide RNA complex together with a donor nucleic acid comprising a nucleotide sequence that corrects the deleterious mutation (e.g., a donor nucleic acid comprising a nucleotide sequence that encodes a functional copy of the protein encoded by the defective allele), can be used to correct the deleterious mutation, e.g., via homology-directed repair (HDR).
  • HDR homology-directed repair
  • the gene products are an RNA-guided endonuclease and 2 separate
  • sgRNAs where the 2 separate sgRNAs provide for deletion of a target nucleic acid via nonhomologous end joining (NHEJ).
  • NHEJ nonhomologous end joining
  • the gene products are: i) an RNA-guided endonuclease; and ii) one guide
  • the guide RNA is a single-molecule (or “single guide”) guide RNA (an “sgRNA”). In some cases, the guide RNA is a dual-molecule (or “dual-guide”) guide RNA (“dgRNA").
  • the gene products are: i) an RNA-guided endonuclease; and ii) 2 separate sgRNAs, where the 2 separate sgRNAs provide for deletion of a target nucleic acid via nonhomologous end joining (NHEJ).
  • the guide RNAs are sgRNAs.
  • the guide RNAs are dgRNAs.
  • the gene products are: i) a Cpf 1 polypeptide; and ii) a guide RNA
  • the present disclosure provides a method of modifying a target nucleic acid in a retinal cell in an individual, where the target nucleic acid comprises a deleterious mutation, the method comprising administering to the individual (e.g., by intraocular; intra vitreal; etc.
  • an rAAV virion of the present disclosure where the rAAV virion comprises a heterologous nucleic acid comprising: i) a nucleotide sequence encoding an RNA-guided endonuclease (e.g., a Cas9 endonuclease); ii) a nucleotide sequence encoding a sgRNA that comprises a nucleotide sequence that is complementary to the target nucleic acid; and iii) a nucleotide sequence encoding a donor DNA template that comprises a nucleotide sequence that corrects the deleterious mutation.
  • Administration of the rAAV virion results in correction of the deleterious mutation in the target nucleic acid by HDR.
  • the present disclosure provides a method of modifying a target nucleic acid in a retinal cell in an individual, where the target nucleic acid comprises a deleterious mutation, the method comprising administering to the individual (e.g., by intraocular; intra vitreal; etc.
  • an rAAV virion of the present disclosure where the rAAV virion comprises a heterologous nucleic acid comprising: i) a nucleotide sequence encoding an RNA-guided endonuclease (e.g., a Cas9 endonuclease); ii) a nucleotide sequence encoding a first sgRNA that comprises a nucleotide sequence that is complementary to a first sequence in the target nucleic acid; and iii) a nucleotide sequence encoding a second sgRNA that comprises a nucleotide sequence that is complementary to a second sequence in the target nucleic acid.
  • Administration of the rAAV virion results in excision of the deleterious mutation in the target nucleic acid by NHEJ.
  • a nucleotide sequence encoding a gene product of interest is operably linked to a transcriptional control element.
  • a nucleotide sequence encoding a gene product of interest is operably linked to a constitutive promoter.
  • a nucleotide sequence encoding a gene product of interest is operably linked to an inducible promoter.
  • a nucleotide sequence encoding a gene product of interest is operably linked to a tissue-specific or cell type-specific regulatory element.
  • a nucleotide sequence encoding a gene product of interest is operably linked to a retinal cell-specific promoter.
  • a nucleotide sequence encoding a gene product of interest is operably linked to a photoreceptor-specific regulatory element (e.g., a photoreceptor-specific promoter), e.g., a regulatory element that confers selective expression of the operably linked gene in a photoreceptor cell.
  • a photoreceptor-specific regulatory element e.g., a photoreceptor-specific promoter
  • Suitable photoreceptor-specific regulatory elements include, e.g., a rhodopsin promoter; a rhodopsin kinase promoter (Young et al. (2003) Ophthalmol. Vis. Sci. 44:4076); a beta phosphodiesterase gene promoter (Nicoud et al. (2007) /. Gene Med.
  • a retinitis pigmentosa gene promoter (Nicoud et al. (2007) supra); an interphotoreceptor retinoid-binding protein (IRBP) gene enhancer (Nicoud et al. (2007) supra); an IRBP gene promoter (Yokoyama et al. (1992) Exp Eye Res. 55:225).
  • IRBP interphotoreceptor retinoid-binding protein
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising: a) a subject rAAV virion, as described above; and b) a pharmaceutically acceptable carrier, diluent, excipient, or buffer.
  • the pharmaceutically acceptable carrier, diluent, excipient, or buffer is suitable for use in a human.
  • excipients include any pharmaceutical agent that can be administered without undue toxicity.
  • Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, glycerol and ethanol.
  • Pharmaceutically acceptable salts can be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.
  • the present disclosure provides a method of delivering a gene product to a retinal cell in an individual, the method comprising administering to the individual a subject rAAV virion as described above.
  • the gene product can be a polypeptide or an interfering RNA (e.g., an shRNA, an siRNA, and the like), an aptamer, or a site-specific endonuclease (e.g., an RNA-guided endonuclease), as described above.
  • Delivering a gene product to a retinal cell can provide for treatment of a retinal disease.
  • the retinal cell can be a photoreceptor, a retinal ganglion cell, a Muller cell, a bipolar cell, an amacrine cell, a horizontal cell, or a retinal pigmented epithelial cell.
  • the retinal cell is a photoreceptor cell, e.g., a rod or cone cell.
  • the present disclosure provides a method modifying a target nucleic acid in a retinal cell, the method comprising contacting the retinal cell with: 1) an rAAV virion of the present disclosure, wherein the rAAV virion comprises a heterologous nucleic acid comprising a nucleotide sequence encoding an RNA-guided endonuclease that binds a guide RNA; and 2) the guide RNA.
  • the present disclosure provides a method modifying a target nucleic acid in a retinal cell, the method comprising contacting the retinal cell with an rAAV virion of the present disclosure, wherein the rAAV virion comprises a heterologous nucleic acid comprising a nucleotide sequence encoding: i) an RNA-guided endonuclease that binds a guide RNA; and ii) the guide RNA.
  • the method comprises contacting the retinal cell with a donor DNA template.
  • the RNA-guided endonuclease is a Cas9 polypeptide.
  • the guide RNA is a single-guide RNA.
  • the present disclosure provides a method of treating an ocular disease (e.g., a retinal disease), the method comprising administering to an individual in need thereof an effective amount of a subject rAAV virion as described above.
  • a subject rAAV virion can be
  • intraocular injection e.g. by intravitreal injection, by subretinal injection, by suprachoroidal injection, or by any other convenient mode or route of administration.
  • Other convenient modes or routes of administration include, e.g., intravenous, intranasal, etc.
  • a "therapeutically effective amount” will fall in a relatively broad range that can be determined through experimentation and/or clinical trials.
  • a therapeutically effective dose will be on the order of from about 10 6 to about 10 15 of the rAAV virions, e.g., from about 10 s to 10 12 rAAV virions.
  • a therapeutically effective dose will be on the order of from about 10 6 viral genomes (vg) to about 10 15 vg of the rAAV virions, e.g., from about 10 s vg to 10 12 vg.
  • an effective amount of rAAV virions to be delivered to cells will be on the order of from about 10 s to about 10 13 of the rAAV virions.
  • an effective amount of rAAV virions to be delivered to cells will be on the order of from about 10 s to about 10 13 vg of the rAAV virions.
  • an effective amount of rAAV virions to be delivered to cells will be on the order of from about 10 vg/cell to about 10 4 vg/cell.
  • Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves.
  • more than one administration e.g., two, three, four or more
  • administrations may be employed to achieve the desired level of gene expression.
  • the more than one administration is administered at various intervals, e.g., daily, weekly, twice monthly, monthly, every 3 months, every 6 months, yearly, etc.
  • multiple administrations are administered over a period of time of from 1 month to 2 months, from 2 months to 4 months, from 4 months to 8 months, from 8 months to 12 months, from 1 year to 2 years, from 2 years to 5 years, or more than 5 years.
  • Ocular diseases that can be treated using a subject method include, but are not limited to, acute macular neuroretinopathy; Behcet's disease; choroidal neovascularization; diabetic uveitis; histoplasmosis; macular degeneration, such as acute macular degeneration, non-exudative age related macular degeneration and exudative age related macular degeneration; edema, such as macular edema, cystoid macular edema and diabetic macular edema; multifocal choroiditis; ocular trauma which affects a posterior ocular site or location; ocular tumors; retinal disorders, such as central retinal vein occlusion, diabetic retinopathy (including proliferative diabetic retinopathy), proliferative vitreoretinopathy (PVR), retinal arterial occlusive disease, retinal detachment, uveitic retinal disease; sympathetic opthalmia; Vogt Koyanagi
  • the present disclosure provides methods of treating retinal disease.
  • the methods are not limited to:
  • Non-limiting methods for assessing treatment of retinal diseases include measuring functional changes, e.g. changes in visual acuity (e.g. BCVA), visual field (e.g. visual field perimetry), electrophysiological responsiveness to light and dark (e.g. ERG, VEP), color vision, and/or contrast sensitivity; measuring changes in anatomy or health using anatomical and/or photographic measures, e.g. OCT, fundus photography, and/or autofluorescence; and measuring ocular motility (e.g. nystagmus, fixation preference, and stability).
  • functional changes e.g. changes in visual acuity (e.g. BCVA), visual field (e.g. visual field perimetry), electrophysiological responsiveness to light and dark (e.g. ERG, VEP), color vision, and/or contrast sensitivity
  • measuring changes in anatomy or health using anatomical and/or photographic measures e.g. OCT, fundus photography, and/or autofluorescence
  • ocular motility e
  • an effective amount of rAAV virions by testing for an effect on one or more parameters, e.g. visual acuity, visual field, electrophysiological responsiveness to light and dark, color vision, contrast sensitivity, anatomy, retinal health and vasculature, ocular motility, fixation preference, and stability.
  • administering an effective amount of an rAAV virion of the present disclosure results in a decrease in the rate of loss of retinal function, anatomical integrity, or retinal health, e.g. a 2-fold, 3-fold, 4-fold, or 5-fold or more decrease in the rate of loss and hence progression of disease, e.g.
  • administering an effective amount of an rAAV virion of the present disclosure results in a gain in retinal function, an improvement in retinal anatomy or health, and/or a stabilization in ocular motility, e.g. a 2-fold, 3-fold, 4-fold or 5-fold improvement or more in retinal function, retinal anatomy or health, and/or stability of the orbital, e.g. a 10-fold improvement or more in retinal function, retinal anatomy or health, and/or stability of the orbital.
  • the present disclosure provides an isolated nucleic acid comprising a nucleotide
  • a subject isolated nucleic acid can be an AAV vector, e.g., a recombinant AAV vector.
  • a variant AAV capsid protein encoded by a subject nucleic acid has an insertion peptide of from about 5 amino acids to about 20 amino acids in length is inserted into the GH loop of an AAV capsid.
  • the insertion peptide has a length of 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, or 20 amino acids.
  • Suitable insertion peptides are as described above.
  • Suitable insertion peptides include a peptide of any one of Formulas I-VI, as described above.
  • a variant AAV capsid protein encoded by a subject nucleic acid comprises a replacement of from about 5 amino acids to about 20 amino acids in the GH loop or loop IV relative to a corresponding parental AAV capsid protein with a heterologous peptide of from about 5 amino acids to about 20 amino acids, where suitable heterologous peptides include a peptide of any one of Formulas I-VI, as described above.
  • a subject recombinant AAV vector can be used to generate a subject recombinant AAV virion, as described above.
  • the present disclosure provides a recombinant AAV vector that, when introduced into a suitable cell, can provide for production of a subject recombinant AAV virion.
  • the present invention further provides host cells, e.g., isolated (genetically modified) host cells, comprising a subject nucleic acid.
  • a subject host cell can be an isolated cell, e.g., a cell in in vitro culture.
  • a subject host cell is useful for producing a subject rAAV virion, as described below. Where a subject host cell is used to produce a subject rAAV virion, it is referred to as a "packaging cell.”
  • a subject host cell is stably genetically modified with a subject nucleic acid.
  • a subject host cell is transiently genetically modified with a subject nucleic acid.
  • a subject nucleic acid is introduced stably or transiently into a host cell, using
  • a subject nucleic acid will generally further include a selectable marker, e.g., any of several well-known selectable markers such as neomycin resistance, and the like.
  • a selectable marker e.g., any of several well-known selectable markers such as neomycin resistance, and the like.
  • a subject host cell is generated by introducing a subject nucleic acid into any of a variety of cells, e.g., mammalian cells, including, e.g., murine cells, and primate cells (e.g., human cells).
  • Suitable mammalian cells include, but are not limited to, primary cells and cell lines, where suitable cell lines include, but are not limited to, 293 cells, 293T cells, COS cells, HeLa cells, Vero cells, 3T3 mouse fibroblasts, C3H10T1/2 fibroblasts, CHO cells, and the like.
  • suitable host cells include, e.g., HeLa cells (e.g., American Type Culture Collection (ATCC) No.
  • ATCC American Type Culture Collection
  • CCL-2 CHO cells
  • CHO cells e.g., ATCC Nos. CRL9618, CCL61, CRL9096
  • 293 cells e.g., ATCC No. CRL-1573
  • Vero cells e.g., ATCC No. CRL-1658
  • Huh-7 cells e.g., BHK cells (e.g., ATCC No. CCL10), PC12 cells (ATCC No.
  • a subject host cell can also be made using a baculovirus to infect insect cells such as Sf9 cells, which produce AAV (see, e.g., U.S. Patent No. 7,271,002; US patent application 12/297,958)
  • a subject genetically modified host cell includes, in addition to a nucleic acid comprising a nucleotide sequence encoding a variant AAV capsid protein, as described above, a nucleic acid that comprises a nucleotide sequence encoding one or more AAV rep proteins.
  • a subject host cell further comprises an rAAV vector.
  • An rAAV virion can be generated using a subject host cell. Methods of generating an rAAV virion are described in, e.g., U.S. Patent Publication No. 2005/0053922 and U.S. Patent Publication No. 2009/0202490. Examples of Non-Limiting Aspects of the Disclosure
  • a recombinant adeno-associated virus (rAAV) virion comprising: a) a variant
  • AAV capsid protein wherein the variant AAV capsid protein comprises an insertion of a heterologous peptide of any one of Formulas I- VI, and wherein the variant capsid protein confers increased infectivity of a retinal cell compared to the infectivity of the retinal cell by a control AAV virion comprising the corresponding parental AAV capsid protein; and b) a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous gene product.
  • Aspect 2 The rAAV virion of aspect 1, wherein the rAAV virion exhibits at least 5-fold increased infectivity of a retinal cell compared to the infectivity of the retinal cell by a control AAV virion comprising the corresponding parental AAV capsid protein.
  • Aspect 3 The rAAV virion of aspect 1, wherein the rAAV virion exhibits at least 10- fold increased infectivity of a retinal cell compared to the infectivity of the retinal cell by an AAV virion comprising the corresponding parental AAV capsid protein.
  • Aspect 4 The rAAV virion of aspect 1 , wherein the insertion of the heterologous peptide replaces a contiguous stretch of from 5 amino acids to 20 amino acids of the parental AAV capsid protein.
  • Aspect 5 The rAAV virion of aspect 1, wherein the insertion site is between amino acids corresponding to amino acids 570 and 611 of VPl of AAV2, or the corresponding position in the capsid protein of another AAV serotype.
  • Aspect 6 The rAAV virion of aspect 4, wherein the insertion site is located between amino acids corresponding to amino acids 587 and 588 of VPl of AAV2, or the corresponding position in the capsid protein of another AAV serotype; or wherein the insertion site is located between amino acids corresponding to amino acids 585 and 598 of VPl of AAV2, or the corresponding position in the capsid protein of another AAV serotype.
  • Aspect 7 The rAAV virion of any one of aspects 1-6, wherein gene product is an
  • Aspect 8 The rAAV virion of any one of aspects 1-6, wherein the gene product is a polypeptide.
  • Aspect 9 The rAAV virion of aspect 8, wherein the polypeptide is a neuroprotective polypeptide, an anti-angiogenic polypeptide, or a polypeptide that enhances function of a retinal cell.
  • Aspect 10 The rAAV virion of aspect 8, wherein the polypeptide is an RNA-guided endonuclease selected from a type II CRISPR/Cas polypeptide, a type V CRISPR/Cas polypeptide, and a type VI CRISPR/Cas polypeptide.
  • the polypeptide is an RNA-guided endonuclease selected from a type II CRISPR/Cas polypeptide, a type V CRISPR/Cas polypeptide, and a type VI CRISPR/Cas polypeptide.
  • Aspect 11 The rAAV virion of aspect 10, wherein the RNA-guided endonuclease is an enzymatically inactive type II CRISPR/Cas polypeptide.
  • Aspect 12 The rAAV virion of aspect 10, wherein the gene product is an RNA-guided endonuclease and a guide RNA.
  • Aspect 13 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide is a peptide of Formula I: LA(L/N)(I/Q)(Q/E)(D/H)(S/V)(M/K)(R N)A (SEQ ID NO:
  • Aspect 14 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide comprises (21) LALIQDSMRA (SEQ ID NO: 35) or (22) LANQEHVKNA (SEQ ID NO: 2).
  • Aspect 15 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide is a peptide of Formula II: TX1X2X3X4X5X6X7X8GLX9 (SEQ ID NO: 137), where:
  • X 2 is V, E, P, G, D, M, A, or S;
  • X 3 is M, V, Y, H, G, S, or D;
  • X 4 is R, D, S, G, V, Y, T, H, or M;
  • Xs is S, L, G, T, Q, P, or A;
  • X 6 is T, A, S, M, D, Q, or H;
  • X 7 is N, G, S, L, M, P, G, or A;
  • Xs is S, G, D, N, A, I, P, or T;
  • X 9 is S or N.
  • Aspect 16 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide comprises: (1) TGVMRSTNSGLN (SEQ ID NO: 6); (2) TGEVDLAGGGLS (SEQ ID No: 7); (3) TSPYSGSSDGLS (SEQ ID NO: 8); (4) TGGHDSSLDGLS (SEQ ID NO: 9); (5) TGDGGTTMNGLS (SEQ ID NO: 98); (6) TGGHGSAPDGLS (SEQ ID NO: 99); (7)
  • TGMHVTMMAGLN (SEQ ID NO: 100); (8) TGASYLDNSGLS (SEQ ID NO: 101); (9) TVVSTQAGIGLS (SEQ ID NO: 135); (10) TGVMHSQASGLS (SEQ ID NO: 21); (11) TGDGSPAAPGLS (SEQ ID NO: 22); or (12) TGSDMAHGTGLS (SEQ ID NO: 23)
  • Aspect 17 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide is a peptide of Formula III: TGX1X2X3X+X5X6X7GLS (SEQ ID NO: 138), where:
  • Xi is V, E, P, G, D, M, A, or S;
  • X 2 is M, V, Y, H, G, S, or D;
  • X 3 is R, D, S, G, V, Y, T, H, or M;
  • X 4 is S, L, G, T, Q, P, or A;
  • Xs is T, A, S, M, D, Q, or H;
  • X 6 is N, G, S, L, M, P, G, or A;
  • X 7 is S, G, D, N, A, I, P, or T.
  • Aspect 18 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide comprises: (2) TGEVDLAGGGLS (SEQ ID NO: 7); (4) TGGHDSSLDGLS (SEQ ID NO: 9); (5) TGDGGTTMNGLS (SEQ ID NO: 98); (6) TGGHGSAPDGLS (SEQ ID NO: 99); (8) TGASYLDNSGLS (SEQ ID NO: 101); (10) TGVMHSQASGLS (SEQ ID NO: 21); (11)
  • TGDGSPAAPGLS SEQ ID NO: 22
  • TGSDMAHGTGLS SEQ ID NO: 23
  • Aspect 19 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide is a peptide of Formula IV: X1GX2X3X4X5X6X7X8GLSPX9TX10X11 (SEQ ID NO: 139), where
  • X 2 is L, S,A, or G;
  • X 3 is D or V
  • X 4 is A, G, or P;
  • Xs is T or D
  • X 6 is R or Y
  • X 7 is D, T, or G
  • Xs is H, R, or T;
  • X 9 is V or A
  • X 11 is T or A.
  • Aspect 20 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide comprises: (13) TGLDATRDHGLSPVTGT (SEQ ID NO: 24); (14)
  • Aspect 21 The rAAV virion of any one of aspects 1-12, wherein the heterologous peptide is a peptide of Formula V: TGXiDX 2 TRX 3 X 4 GLSPVTGT (SEQ ID NO: 140), where
  • Xi is L, S,A, or G
  • X 2 is A, G, or P;
  • X 3 is D, T, or G
  • X 4 is H, R, or T
  • Aspect 22 The rAAV virion of any one of aspects 1-12, wherein the heterologous
  • peptide is a peptide of Formula VI: LQX1X2X3RX4X5X6X7X8X9VNX10Q (SEQ ID NO: 141), where
  • X 2 is N, G, or A
  • X 3 is A, V, N, or D;
  • X 4 is P, I, or Q
  • Xs is A, P, or V;
  • X 6 is S, T, or G
  • X 7 is T or V
  • Xs is E, L, A, or V;
  • X 9 is S, E, D, or V;
  • X10 is F, G, T, or C.
  • Aspect 23 The rAAV virion of any one of aspects 1-12, wherein the heterologous
  • peptide comprises: (17) LQKNARPASTESVNFQ (SEQ ID NO: 28); (18)
  • LQRGVRIPSVLEVNGQ (SEQ ID NO: 29); (19) LQRGNRPVTTADVNTQ (SEQ ID NO: 30); or (20) LQKADRQPGVVVVNCQ (SEQ ID NO: 31).
  • a pharmaceutical composition comprising:
  • Aspect 25 A method of delivering a gene product to a retinal cell in an individual, the method comprising administering to the individual a recombinant adeno-associated virus (rAAV) virion according any one of aspects 1-23 or the composition of aspect 24.
  • rAAV adeno-associated virus
  • Aspect 26 The method of aspect 25, wherein the gene product is a polypeptide.
  • Aspect 27 The method of aspect 25, wherein the gene product is a short interfering
  • Aspect 28 The method of aspect 26, wherein the polypeptide is a neuroprotective factor, an anti-angiogenic polypeptide, an anti-apoptotic factor, or a polypeptide that enhances function of a retinal cell.
  • Aspect 29 The method of aspect 26, wherein the polypeptide is glial derived
  • fibroblast growth factor 2 fibroblast growth factor 2
  • neurturin ciliary neurotrophic factor
  • nerve growth factor brain derived neurotrophic factor
  • epidermal growth factor rhodopsin
  • X-linked inhibitor of apoptosis retinoschisin, RPE65, retinitis pigmentosa GTPase-interacting protein-1, peripherin, peripherin-2, a rhodopsin, RdCVF, retinitis pigmentosa GTPase regulator (RPGR), or Sonic hedgehog.
  • RPGR retinitis pigmentosa GTPase regulator
  • Aspect 30 The method of aspect 26, wherein the polypeptide is an RNA -guided
  • a method of treating an ocular disease comprising administering to an individual in need thereof an effective amount of a recombinant adeno-associated virus (rAAV) virion according to any one of aspects 1-23 or the composition of aspect 24.
  • rAAV recombinant adeno-associated virus
  • Aspect 32 The method of aspect 31, wherein said administering is by intraocular
  • Aspect 33 The method of aspect 31, wherein said administering is by intravitreal
  • Aspect 34 The method of any one of aspects 31-33, wherein the ocular disease is
  • glaucoma retinitis pigmentosa
  • macular degeneration retinoschisis
  • Leber's Congenital Amaurosis diabetic retinopathy
  • achromotopsia or color blindness.
  • Aspect 35 An isolated nucleic acid comprising a nucleotide sequence that encodes a variant adeno-associated virus (AAV) capsid protein, wherein the variant AAV capsid protein comprises an insertion of from about 5 amino acids to about 20 amino acids in the capsid protein GH loop relative to a corresponding parental AAV capsid protein, and wherein the variant capsid protein, when present in an AAV virion, provides for increased infectivity of the AAV virion of a retinal cell, and wherein the amino acid insertion is in the GH loop of a native AAV capsid, wherein the insertion is a peptide of any one of Formulas I- VI.
  • AAV adeno-associated virus
  • Aspect 36 The isolated nucleic acid of aspect 35, wherein the insertion site is between amino acids 587 and 588 of AAV2, between amino acids 585 and 598 of AAV2, between amino acids 590 and 591 of AAV1, between amino acids 575 and 576 of AAV5, between amino acids 590 and 591 of AAV6, between amino acids 589 and 590 of AAV7, between amino acids 590 and 591 of AAV8, between amino acids 588 and 589 of AAV9, or between amino acids 588 and 589 of AAV10.
  • Aspect 37 An isolated, genetically modified host cell comprising the nucleic acid of aspect 35 or aspect 36.
  • a variant adeno-associated virus (AAV) capsid protein wherein the variant
  • AAV capsid protein comprises an insertion of from about 5 amino acids to about 20 amino acids wherein the amino acid insertion is in the GH loop of a native AAV capsid, wherein the insertion is a peptide of any one of Formulas I- VI.
  • a recombinant adeno-associated virus (rAAV) virion comprising:
  • b) a heterologous nucleic acid comprising a nucleotide sequence encoding a
  • Aspect 40 The rAAV virion of aspect 39, wherein the rAAV virion exhibits at least 5- fold increased infectivity of a retinal cell compared to the infectivity of the retinal cell by a control AAV virion comprising the corresponding parental AAV capsid protein.
  • Aspect 41 The rAAV virion of aspect 39, wherein the rAAV virion exhibits at least 10- fold increased infectivity of a retinal cell compared to the infectivity of the retinal cell by an AAV virion comprising the corresponding parental AAV capsid protein.
  • Aspect 42 The rAAV virion of any one of aspects 39-41, wherein the insertion of the heterologous peptide replaces a contiguous stretch of from 5 amino acids to 20 amino acids of the parental AAV capsid protein.
  • Aspect 43 The rAAV virion of any one of aspects 39-42, wherein the insertion site is between amino acids corresponding to amino acids 570 and 611 of VP1 of AAV2, or the corresponding position in the capsid protein of another AAV serotype.
  • Aspect 44 The rAAV virion of aspect 43, wherein the insertion site is located between amino acids corresponding to amino acids 587 and 588 of VP1 of AAV2, or the corresponding position in the capsid protein of another AAV serotype; or wherein the insertion site is located between amino acids corresponding to amino acids 585 and 598 of VP1 of AAV2, or the corresponding position in the capsid protein of another AAV serotype.
  • Aspect 45 The rAAV virion of any one of aspects 39-44, wherein gene product is an interfering RNA.
  • Aspect 46 The rAAV virion of any one of aspects 39-44, wherein gene product is an aptamer.
  • Aspect 47 The rAAV virion of any one of aspects 39-44, wherein the gene product is a polypeptide.
  • Aspect 48 The rAAV virion of aspect 47, wherein the polypeptide is a neuroprotective polypeptide, an anti-angiogenic polypeptide, or a polypeptide that enhances function of a retinal cell.
  • Aspect 49 The rAAV virion of aspect 47, wherein the polypeptide is an RNA-guided endonuclease selected from a type II CRISPR/Cas polypeptide, a type V CRISPR/Cas polypeptide, and a type VI CRISPR/Cas polypeptide.
  • Aspect 50 The rAAV virion of aspect 49, wherein the RNA-guided endonuclease is an enzymatically inactive type II CRISPR/Cas polypeptide.
  • Aspect 51 The rAAV virion of one of aspects 39-44, wherein the gene product is an
  • RNA-guided endonuclease and a guide RNA RNA-guided endonuclease and a guide RNA.
  • Aspect 52 The rAAV virion of any one of aspects 39-51 , wherein the heterologous peptide comprises: (17) LQKNARPASTESVNFQ (SEQ ID NO: 28); (18)
  • LQRGVRIPSVLEVNGQ (SEQ ID NO: 29); (19) LQRGNRPVTTADVNTQ (SEQ ID NO: 30); or (20) LQKADRQPGVVVVNCQ (SEQ ID NO: 31).
  • a pharmaceutical composition comprising:
  • Aspect 54 A method of delivering a gene product to a retinal cell in an individual, the method comprising administering to the individual a recombinant adeno-associated virus (rAAV) virion according any one of aspects 39-52 or the composition of aspect 53.
  • rAAV adeno-associated virus
  • Aspect 55 The method of aspect 54, wherein the gene product is a polypeptide.
  • Aspect 56 The method of aspect 54, wherein the gene product is a short interfering
  • RNA or an aptamer RNA or an aptamer.
  • Aspect 57 The method of aspect 55, wherein the polypeptide is a neuroprotective factor, an anti-angiogenic polypeptide, an anti-apoptotic factor, or a polypeptide that enhances function of a retinal cell.
  • Aspect 58 The method of aspect 57, wherein the polypeptide is glial derived
  • Aspect 59 The method of aspect 55, wherein the polypeptide is an RNA-guided endonuclease.
  • Aspect 60 A method of treating an ocular disease, the method comprising administering to an individual in need thereof an effective amount of a recombinant adeno-associated virus (rAAV) virion according to any one of aspects 39-52 or the composition of aspect 53.
  • rAAV recombinant adeno-associated virus
  • Aspect 61 The method of aspect 60, wherein said administering is by intraocular
  • Aspect 62 The method of aspect 60, wherein said administering is by intravitreal
  • Aspect 63 The method of any one of aspects 60-62, wherein the ocular disease is
  • glaucoma glaucoma, retinitis pigmentosa, macular degeneration, retinoschisis, Leber's Congenital
  • Amaurosis diabetic retinopathy, achromotopsia, or color blindness.
  • Standard abbreviations may be used, e.g., bp, base pair(s); kb, kilobase(s); pi, picoliter(s); s or sec, second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); kb, kilobase(s); bp, base pair(s); nt, nucleotide(s); i.m., intramuscular(ly); i.p., intraperitoneal(ly); s.c, subcutaneous(ly); and the like.
  • Example 1 AAV virions comprising variant AAV capsids
  • a number of variants of AAV capsids were derived through a directed evolution
  • AAV virions comprising the variant AAV capsids infect the primate retina, e.g., when administered via intravitreal injection.
  • Primates are an important preclinical model for human retinal disease, with a fovea for high acuity vision, similar to humans.
  • AAV virions comprising variant AAV capsids were identified by screening. Five
  • Virus was packaged such that each viral genome was encapsidated within the capsid protein shell that that genome encoded, as previously described Koerber et al. (2008) supra; Fowler et al. Nat Protoc 9, 2267-2284 (2014). Therefore functional improvements identified through selection can be linked to the genome sequence contained within the viral capsid.
  • AAV vectors were produced by triple transient transfection of HEK293T cells, purified via iodixanol density centrifugation, and buffer exchanged into PBS by Amicon filtration. DNase-resistant viral genomic titers were measured by quantitative real time PCR using a BioRad iCycler.
  • capsid sequences were recovered by PCR from harvested cells using primers HindIII_Fl and NotI_Rl, AscI_Rl, or SpeI_Rl, with reverse primers being specific to unique AAV backbones, in order to maintain separation of groups of libraries. PCR amplicons were then digested, and recloned into the backbone. RPE cells were separated from retinal tissue, and tissue was frozen. Retinal tissue was embedded and sectioned on a cryostat to isolate photoreceptors in the outer nuclear layer. DNA was then collected from the isolated photoreceptors or RPE, and cap genes were PCR amplified. Recovered cap genes were used for subsequent AAV packaging.
  • FIG. 1 Illustration of the directed evolution methodology used to develop primate
  • Peptide display libraries were created, packaged into AAV vectors, and injected into the primate eye via intravitreal injections. Iterative round of selection were used to positively select AAV variants from the pool of vectors. Three rounds of selection were followed by a round of error prone PCR, followed by additional selection rounds.
  • Illumina deep sequencing was used to identify variants that increased over the rounds in relative representation in the library of AAV variants.
  • An increase of representation in the viral library indicates positive selection and ability to infect the primate retina from the vitreous.
  • a -75-85 base pair region containing the 7mer insertion or Loop Swap mutation site was PCR amplified from harvested DNA.
  • Primers included Illumina adapter sequences containing unique barcodes to allow for multiplexing of amplicons from multiple rounds of selection. PCR amplicons were purified and sequenced with a 100-cycle single -read run on an Illumina HiSeq 2500.
  • Custom Python code was written to translate DNA sequences into amino acid sequences, and to identify and count reads containing unique 7mer insert sequences. Read counts were normalized by the total number of reads in the run. Python and Pandas were used to analyze dynamics of directed evolution and create plots.
  • AAV vectors can be used for gene augmentation therapies for retinal degenerative diseases including retinitis pigmentosa, Leber Congenital Amaurosis, Rod-cone dystrophy, cone dystrophy, achromatopsia, X-linked retinoschisis, CRB 1, optogenetic therapies, expression of trophic and survival factors such as GDNF, BDNF, FGF, RdCVF, RdCVFL, XIAP, and expression of blockers of neovascularization such as sFLT.
  • the vectors can also be used to deliver gene editing tools such as CRISPR/Cas9 for gene correction or the creation of additional models of retinal disease.
  • Barcodes were PCR amplified directly from DNA or cDNA (created from mRNA using
  • FIG. 9 provides Table 1 ;
  • FIG. 10 provides Table 2.
  • Table 1 provides a ranking of primate -derived variants and controls recovered from photoreceptors following injection of a GFP-Barcode library.
  • Table 2 provides a ranking of primate-derived variants and controls recovered from RPE cells following injection of a GFP- Barcode library.
  • the library contained individual variants packaged with GFP fused to a unique DNA barcode. Polymerase chain reaction (PCR) was used to amplify barcodes from DNA recovered from specific cell types in the retina. "Region" in Tables 1 and 2 indicates the region from which the DNA was recovered. The fold increase of reads of each of the variants was calculated by dividing number of reads for each unique barcode in the recovered cells
  • FIG. 11 GFP expression of GFP-barcoded libraries in primate retina.
  • GFP expression resulting from intravitreal injection of pooled, GFP-barcoded library (which contains all the tested viruses) was located primarily in the outer retina, with a tropism that was directed more toward the outer retina than expression of AAV24YF.
  • Cynomolgous monkeys between 4-10 years old were used for all studies, and intravitreal injections were made.
  • the monkey used for fluorophore expression received daily subcutaneous injections of cyclosporine at a dose of 6 mg/kg for immune suppression, and adjusted based on blood trough levels to within a 150-200 ng/ml target range.
  • ophthalmoscopic images (Spectralis HRA, Heidelberg Engineering) were obtained from the two retinas at 3 weeks after injection, with autofluorescence settings, which leads to effective tdTomato and GFP visualization.
  • the monkey was euthanized, both retinas were lightly fixed in 4% paraformaldehyde, and tissue was examined by confocal microscopy.
  • euthanasia was achieved by administering an IV overdose of sodium pentobarbital (75 mg kg-1), as recommended by the Panel on Euthanasia of the
  • the nonhuman primate is a critical preclinical model for human therapeutic development, as it is most closely related to, and has a retinal anatomy similar to that of humans.
  • primates are the only large animal model that possesses a fovea, the specialized high acuity area of the retina that is most important for daily activities such as reading, is critical to quality of life, and is lost in numerous retinal degenerations.
  • the species specificity observed in the canine study motivated us to pursue an additional course of directed evolution in primate retina.
  • Nine libraries were packaged and included in the primate screen: EP2, EP5, EP6, EP8, EP9, EP-Ancestral, AAV2-7mer, Ancestral-7mer (Santiago-Ortiz et al.
  • FIG. 12C Sixteen variants, from these 5 libraries (Fig. 12C), were selected to be included in a secondary round of selection with GFP-barcoded libraries, along with AAV2, AAV2-4YF+TV, AAV4 and AAV5 as controls.
  • This new library was injected in both eyes of a primate, and 3 weeks after injection, biopsies were collected from locations across the retina (Fig. 12D).
  • GFP expression resulting from injection of the GFP-barcode libraries was primarily found in photoreceptors, as well as some inner retinal cells, a tropism that is shifted from AAV2 or 7m8, which yielded stronger inner retinal expression (Fig. 12E).
  • Fig. 12A-12F Directed evolution of AAV in primate retina.
  • A Deep sequencing of variant libraries revealed convergence of variants over rounds of selection.
  • B In each of the libraries evaluated, a small proportion of variants are overrepresented in the plasmid library.
  • C Scatterplots illustrate the behavior of individual variants at the final round of selection for each of the libraries injected in primate retinas. Variants overrepresented in the original library are colored blue. Variants that had the greatest fold increase in representation in the final round of selection are shown in magenta. Variants that were overrepresented in the original library and increased significantly in representation over rounds of selection are colored orange.
  • FIG. D A map of the primate retina shows the distribution of samples that were collected for rounds of selection and the GFP-barcode library. Color coding of variants is the same as in Fig. 2.
  • E GFP expression resulting from the barcoded library revealed that expression was shifted to an outer retinal tropism in selected variants.
  • F GFP-barcode library injection results, for primate outer retina. The lists of variants are ordered from best (top) to worst (bottom) performing vectors, along with a value indicating the extent to which the variant competed with other vectors, expressed as: % of total in AAV library / % of total in recovered library.
  • 588-LQRGVRIPSVLEVNGQ (SEQ ID NO: 116), outperformed other variants, though it yielded lower viral titers (-5E+11 vg/mL).
  • AAV2-LALIQDSMRA (SEQ ID NO: 117; designated NHP#9), the second ranking variant from the GFP-barcode screen, which packaged at high titers (-5E+13 vg/mL), was therefore selected for a first round of validation studies focusing on ganglion cells of the inner retina and cones of the outer retina. Cone photoreceptors are involved in adult macular degeneration (AMD), the most common cause of blindness in developed countries that are predicted to affect 288 million people worldwide by the year 2040, and are therefore a primary target for retinal gene therapy. NHP#9 was packaged with an SNCG promoter driving tdTomato in RGCs and the pR1.7 promoter driving expression of GFP in cones.
  • Vectors encoding both these constructs were mixed in equal ratios (-1.5E+12 vg/construct/eye, and injected intravitreally in a cynomolgous monkey.
  • a previously described variant, 7m8 (Dalkara et al. (2013) supra) packaged with equal titers of the same constructs was injected into the vitreous of the contralateral eye.
  • Expression of tdTomato reporter in RGC's was lower in NHP#9-injected eyes compared to 7m8, which infected ganglion cells across the expanse of the retina efficiently; however, expression in foveal cones was greatly increased relative to 7m8, indicating a shift in tropism away from the inner retina towards photoreceptors in the outer retina.
  • qRT-PCR performed using the ddCT method, revealed an 11.71 (10.37 - 13.22) fold increase of GFP expression in foveal cones relative to 7m8.
  • Counting of labeled cells performed with Imaris software on images collected from flatmounted retinas, also confirmed a substantial decrease in numbers of transduced ganglion cells and an increase in the number of cones targeted with NHP#9.
  • LQRGVRIPSVLEVNGQ (SEQ ID NO: 118; designated NHP#26) was also tested for validation, although low numbers of viral particles were produced.
  • NHP#26-scCAG- eGFP were injected intravitreally into one eye of a cynomolgous monkey. Although the number of particles injected was low, efficient expression of GFP was observed in the fovea and across the retina (Fig. 13G).
  • NHP#9 Fig 13A
  • fundus imaging of NHP#26 resulted in a disc of GFP expression centered on the foveola (Fig. 13G).
  • FIG. 13A-13Q Validation of evolved AAV variants in primate retina.
  • A-F Co-injection of -1.5E+12 particles of SCNG-tdTomato and -1.5E+12 pR1.7-eGFP packaged in 7m8 and variant NHP#9 in primate retina.
  • Intravitreal injection of 7m8 (A,C,E) resulted in robust tdTomato expression in ganglion cells and expression of GFP in foveal cones.
  • injection of equal number of particles of NHP#9 resulted in reduced ganglion cell expression, and increased GFP expression in cones relative to 7m8 (B,D,F).
  • G Fundus imaging in a primate eye following injection of 5E+10 particles of NHP#26-scCAG-GFP resulted in a disc of GFP expression centered on the fovea, and a punctate pattern of GFP expression across the retina.
  • H Confocal imaging of native GFP expression in the flatmounted fovea.
  • I Confocal imaging of native GFP expression in the area outside of the vascular arcade.
  • J Confocal imaging of native GFP expression in a cryostat section through the fovea.
  • K Native GFP expression in inferior retina, outside the vascular arcade, shows little GFP expression in ganglion cells, but high levels of expression in Muller cells and in photoreceptors in outer retina. Autofluorescence was also observed in RPE.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2018/040115 2017-06-30 2018-06-28 VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF Ceased WO2019006182A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US16/486,681 US20200121746A1 (en) 2017-06-30 2018-06-28 Adeno-associated virus virions with variant capsids and methods of use thereof
CA3053154A CA3053154A1 (en) 2017-06-30 2018-06-28 Adeno-associated virus virions with variant capsids and methods of use thereof
KR1020197027085A KR102766238B1 (ko) 2017-06-30 2018-06-28 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
KR1020257003821A KR20250023600A (ko) 2017-06-30 2018-06-28 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
EP18822630.2A EP3645052A4 (en) 2017-06-30 2018-06-28 ADENO-ASSOCIATED VIRUS VIRIONS WITH ASSOCIATED CAPSIDE VARIANTS AND METHODS OF USE
AU2018290954A AU2018290954B2 (en) 2017-06-30 2018-06-28 Adeno-associated virus virions with variant capsids and methods of use thereof
MX2019010910A MX2019010910A (es) 2017-06-30 2018-06-28 Viriones de virus adenoasociados con capsides variantes y metodos para su uso.
CN201880019175.3A CN110461368A (zh) 2017-06-30 2018-06-28 具有变异衣壳的腺相关病毒病毒体及其使用方法
JP2019568621A JP7744659B2 (ja) 2017-06-30 2018-06-28 バリアントカプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
BR112019019015A BR112019019015A2 (pt) 2017-06-30 2018-06-28 vírions de vírus adeno-associado com capsídeos variantes e seus métodos de uso
US18/167,598 US12310997B2 (en) 2017-06-30 2023-02-10 Compositions and methods of treating ocular diseases
JP2023110850A JP2023126919A (ja) 2017-06-30 2023-07-05 バリアントカプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
AU2023248082A AU2023248082B2 (en) 2017-06-30 2023-10-10 Adeno-associated virus virions with variant capsids and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762527871P 2017-06-30 2017-06-30
US62/527,871 2017-06-30
US201762535042P 2017-07-20 2017-07-20
US62/535,042 2017-07-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/486,681 A-371-Of-International US20200121746A1 (en) 2017-06-30 2018-06-28 Adeno-associated virus virions with variant capsids and methods of use thereof
US18/167,598 Continuation US12310997B2 (en) 2017-06-30 2023-02-10 Compositions and methods of treating ocular diseases

Publications (1)

Publication Number Publication Date
WO2019006182A1 true WO2019006182A1 (en) 2019-01-03

Family

ID=64742248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/040115 Ceased WO2019006182A1 (en) 2017-06-30 2018-06-28 VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF

Country Status (10)

Country Link
US (2) US20200121746A1 (enExample)
EP (1) EP3645052A4 (enExample)
JP (2) JP7744659B2 (enExample)
KR (2) KR20250023600A (enExample)
CN (1) CN110461368A (enExample)
AU (2) AU2018290954B2 (enExample)
BR (1) BR112019019015A2 (enExample)
CA (1) CA3053154A1 (enExample)
MX (1) MX2019010910A (enExample)
WO (1) WO2019006182A1 (enExample)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019158619A1 (en) * 2018-02-15 2019-08-22 Bjoerklund Tomas Modified viral capsids
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2021084133A1 (en) * 2019-10-31 2021-05-06 Universität Bern Aav vector variants for ocular gene delivery
US11149256B2 (en) 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
JP2022528416A (ja) * 2019-04-04 2022-06-10 リジェネックスバイオ インコーポレイテッド 組換えアデノ随伴ウイルス及びその使用
US11739346B2 (en) 2017-04-05 2023-08-29 University Of Massachusetts Minigene therapy
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
US12031147B2 (en) 2020-05-29 2024-07-09 The Regents Of The University Of California Adeno-associated virus virions with variant capsids and methods of use thereof
WO2024191778A1 (en) 2023-03-10 2024-09-19 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
US12116385B2 (en) 2021-10-08 2024-10-15 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
US12146150B2 (en) 2017-09-29 2024-11-19 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
WO2025008323A1 (en) * 2023-07-03 2025-01-09 UCB Biopharma SRL Engineered aav capsid proteins
WO2025049993A1 (en) 2023-08-31 2025-03-06 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2025171227A1 (en) 2024-02-08 2025-08-14 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
US12390539B2 (en) 2019-05-20 2025-08-19 University Of Massachusetts Minigene therapy
JP7791546B2 (ja) 2019-10-31 2025-12-24 ウニベルジテート ベルン 眼遺伝子送達のためのａａｖベクター変異体

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3254703T (lt) * 2011-04-22 2020-05-25 The Regents Of The University Of California Adenoasocijuoto viruso virionai su variantine kapside ir jų panaudojimo būdai
CN113025618B (zh) * 2019-12-24 2024-02-06 朗信启昇(苏州)生物制药有限公司 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
CN113952472A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
US20240150410A1 (en) * 2021-04-13 2024-05-09 Capsida, Inc. Aav compositions having high expression levels in brain
WO2022235970A2 (en) * 2021-05-06 2022-11-10 The Regents Of The University Of California Novel aav serotypes derived from a library screen
CN114195859B (zh) * 2021-12-10 2022-11-18 和元生物技术（上海）股份有限公司 一种适用于特异感染u251细胞的腺相关病毒突变体
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof
EP4442698A4 (en) * 2021-12-28 2025-10-15 Chengdu Origen Biotechnology Co Ltd MODIFIED AAV CAPSID PROTEIN AND ITS USE
AU2023338576A1 (en) * 2022-09-09 2025-02-20 The Regents Of The University Of California Reprogramming tropism via displayed peptides tiling receptor-ligands
CN116621935B (zh) * 2022-12-08 2024-01-26 广州派真生物技术有限公司 腺相关病毒突变体及其应用

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639736A (en) 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
US6399586B1 (en) 1993-07-27 2002-06-04 Hybridon, Inc. Modified VEGF oligonucleotides
US20050053922A1 (en) 2003-06-30 2005-03-10 Schaffer David V. Mutant adeno-associated virus virions and methods of use thereof
US20050075492A1 (en) 2003-08-07 2005-04-07 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US20050266552A1 (en) 2003-12-05 2005-12-01 Doench John G Reagents and methods for identification of RNAi pathway genes and chemical modulators of RNAi
US20050272923A1 (en) 2004-05-06 2005-12-08 Zhang Byoung-Tak Mature microRNA prediction method using bidirectional hidden markov model and medium recording computer program to implement the same
US7271002B2 (en) 2001-11-09 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US20070261127A1 (en) 2005-07-22 2007-11-08 Boyden Edward S Light-activated cation channel and uses thereof
US20080188437A1 (en) 2002-07-24 2008-08-07 The Trustees Of The University Of Pennsylvania Compositions and Methods for siRNA Inhibition of Angiogenesis
US20090202490A1 (en) 2003-06-30 2009-08-13 Schaffer David V Mutant adeno-associated virus virions and methods of use thereof
US20100015095A1 (en) 2006-05-04 2010-01-21 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US7846730B2 (en) 2001-07-17 2010-12-07 Isis Pharmaceuticals, Inc. Antisense modulation of BCL2-associated X protein expression
US7919473B2 (en) 2004-03-12 2011-04-05 Alnylam Pharmaceuticals, Inc. IRNA agents targeting VEGF
US20110143400A1 (en) 2006-09-08 2011-06-16 Opko Ophthalmics, Llc Sirna and methods of manufacture
US20110301073A1 (en) 2010-05-17 2011-12-08 Sangamo Biosciences, Inc. Novel DNA-binding proteins and uses thereof
US20130019325A1 (en) 2010-03-17 2013-01-17 Karl Deisseroth Light-Sensitive Ion-Passing Molecules
US20130347137A1 (en) 2010-11-05 2013-12-26 The Board Of Trustees Of The Leland Stanford Junior University Stabilized Step Function Opsin Proteins and Methods of Using the Same
US20140364338A1 (en) 2011-04-22 2014-12-11 The Regents Of The University Of California Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof
US20150152142A1 (en) * 2009-02-11 2015-06-04 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20150315610A1 (en) * 2012-12-25 2015-11-05 Takara Bio Inc. Aav variant
US20160002302A1 (en) 2010-11-05 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
WO2016141078A1 (en) 2015-03-02 2016-09-09 Avalanche Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
US20160355797A1 (en) 2013-12-12 2016-12-08 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
US20170096683A1 (en) * 2014-05-02 2017-04-06 Genzyme Corporation Aav vectors for retinal and cns gene therapy
WO2017197355A2 (en) * 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
WO2019046069A1 (en) 2017-08-28 2019-03-07 The Regents Of The University Of California ADENO-ASSOCIATED VIRUS CAPSID VARIANTS AND METHODS OF USE

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206016D0 (en) 1992-03-19 1992-04-29 Sandoz Ltd Improvements in or relating to organic compounds
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
EP0927044A4 (en) 1996-04-16 1999-09-08 Immusol Inc DEFINED TARGET VIRAL VECTORS
US6710036B2 (en) 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
EP1690868A1 (en) 1997-10-31 2006-08-16 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
DE19827457C1 (de) 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
ATE294874T1 (de) 1998-09-11 2005-05-15 Univ California Rekombinante adenovirus für gewebespezifische genexpression ins herz
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
DE19933719A1 (de) 1999-07-19 2001-01-25 Medigene Ag Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
US8232081B2 (en) 1999-09-21 2012-07-31 Basf Se Methods and microorganisms for production of panto-compounds
DE19961180C2 (de) 1999-12-18 2002-02-28 Daimler Chrysler Ag Dünnschichtwiderstand mit hohem Temperaturkoeffizienten als passives Halbleiterbauelement für integrierte Schaltungen und Herstellungsverfahren
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US20030149235A1 (en) 2000-11-17 2003-08-07 Baker Andrew Howard Targeting peptides
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
US6962815B2 (en) 2001-01-05 2005-11-08 Children's Hopital Inc. AAV2 vectors and methods
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
SG168422A1 (en) 2001-11-13 2011-02-28 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20050106558A1 (en) 2001-12-21 2005-05-19 Luca Perabo Library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
US6846666B2 (en) 2002-03-21 2005-01-25 Council Of Scientific And Industrial Research Bacterial strain MTCC 5098 and a method of reducing total dissolved solids (TDS) from pulp and paper wastewater effluents using the said strain
WO2003089612A2 (en) 2002-04-17 2003-10-30 University Of Florida Research Foundation, Inc. IMPROVED rAAV VECTORS
WO2003093436A2 (en) 2002-04-30 2003-11-13 University Of Florida Treatment for phenylketonuria
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
US7071172B2 (en) 2002-04-30 2006-07-04 The University Of North Carolina At Chapel Hill Secretion signal vectors
US20060127358A1 (en) 2002-05-01 2006-06-15 Nicholas Muzyczka Raav expression systems and methods for enhancing transduction of mammalian neural cells
US7254489B2 (en) 2002-05-31 2007-08-07 Microsoft Corporation Systems, methods and apparatus for reconstructing phylogentic trees
US7220577B2 (en) 2002-08-28 2007-05-22 University Of Florida Research Foundation, Inc. Modified AAV
US20070172460A1 (en) 2003-03-19 2007-07-26 Jurgen Kleinschmidt Random peptide library displayed on aav vectors
WO2004108922A2 (en) 2003-04-25 2004-12-16 The Trustees Of The University Of Pennsylvania Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
PL2357189T3 (pl) 2003-06-19 2017-08-31 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
JP2007524622A (ja) 2003-06-23 2007-08-30 エイアンドジー ファーマスーティカルズ インコーポレイテッド 抗癌治療に対する腫瘍細胞の感受性を回復させてアポトーシスを誘導するための組成物及び方法
US20050019927A1 (en) 2003-07-13 2005-01-27 Markus Hildinger DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
AU2004276316A1 (en) 2003-09-24 2005-04-07 The Board Of Trustees Of The Leland Stanford Junior University IGF-1 instructs multipotent adult CNS neural stem cells to an oligodendroglial lineage
EP3910063A1 (en) 2003-09-30 2021-11-17 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
CN101124328A (zh) 2004-12-15 2008-02-13 北卡罗来纳查佩尔山大学 嵌合载体
US20100172871A1 (en) 2005-02-17 2010-07-08 Flannery John G Muller Cell Specific Gene Therapy
EP3409296A1 (en) 2005-04-07 2018-12-05 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
CN1966082B (zh) 2006-11-03 2010-06-30 许瑞安 一种防治结直肠癌的基因药物及其制备方法和用途
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
BRPI0810172A2 (pt) 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
EP1985708B1 (en) 2007-04-27 2015-04-15 Universität Rostock Selective targeting of viruses to neural precursor cells
US8632764B2 (en) 2008-04-30 2014-01-21 University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
EP2910637A1 (en) 2008-05-20 2015-08-26 University of Florida Research Foundation, Inc. Vectors for delivery of light-sensitive proteins and methods of use
US20110171262A1 (en) 2008-06-17 2011-07-14 Andrew Christian Bakker Parvoviral capsid with incorporated gly-ala repeat region
CN101532024A (zh) 2009-04-30 2009-09-16 许瑞安 一种用于基因治疗的新型细胞特异性内含microRNA结合序列的基因HAAVmir
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
WO2011117258A2 (en) 2010-03-22 2011-09-29 Association Institut De Myologie Methods of increasing efficiency of vector penetration of target tissue
US8263396B2 (en) 2010-04-01 2012-09-11 Weidong Xiao Methods and compositions for the production of recombinant virus vectors
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
EP2748185A1 (en) 2011-08-24 2014-07-02 The Board of Trustees of The Leland Stanford Junior University New aav capsid proteins for nucleic acid transfer
CA2870736C (en) 2012-04-18 2021-11-02 The Children's Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
JP6385920B2 (ja) 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー アデノ随伴ウイルスプラスミド及びベクター
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
DK2954051T3 (da) * 2013-02-08 2019-07-08 Univ Pennsylvania Modificeret kapsid til genoverførsel til behandling af nethinden
JP6670743B2 (ja) 2013-05-29 2020-03-25 セレクティスＣｅｌｌｅｃｔｉｓ Ｉｉ型ｃｒｉｓｐｒシステムにおける新規のコンパクトなｃａｓ９足場
WO2014194132A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
WO2014200910A2 (en) 2013-06-10 2014-12-18 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
ES2716615T3 (es) 2013-06-28 2019-06-13 Inst Nat Sante Rech Med Métodos para expresar un polinucleótido de interés en la retina de un sujeto
WO2015012501A1 (ko) 2013-07-25 2015-01-29 주식회사 스마트캐스터 비공기압 바퀴
EP3633041A3 (en) 2013-09-26 2020-07-29 University of Florida Research Foundation, Inc. Synthetic combinatorial aav capsid library for targeted gene therapy
NZ758025A (en) 2013-10-11 2022-07-01 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
CA2942776C (en) 2014-03-17 2023-01-24 Adverum Biotechnologies, Inc. Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
CA2951707A1 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
DE102014217790A1 (de) 2014-09-05 2016-03-10 Evonik Degussa Gmbh Verfahren zur Herstellung von hydrosilylierbaren Eugenol-Polyethern und Eugenol-Polyethersiloxanen sowie deren Verwendung
ES2920850T3 (es) * 2015-02-20 2022-08-10 Univ Iowa Res Found Procedimientos y composiciones para el tratamiento de enfermedades oculares genéticas
HRP20201225T1 (hr) 2015-03-06 2020-11-13 Massachusetts Eye & Ear Infirmary Terapije poboljšavanja gena kod nasljedne degeneracije mrežnice uzrokovanu mutacijama u genu prpf31
WO2016154344A1 (en) 2015-03-24 2016-09-29 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
WO2017023724A1 (en) 2015-07-31 2017-02-09 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
MA44546B1 (fr) 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
KR20230039779A (ko) 2016-07-29 2023-03-21 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639872A (en) 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
US5661135A (en) 1993-07-27 1997-08-26 Hybridon, Inc. Human VEGF-specific oligonucleotides
US6399586B1 (en) 1993-07-27 2002-06-04 Hybridon, Inc. Modified VEGF oligonucleotides
US5639736A (en) 1993-07-27 1997-06-17 Hybridon, Inc. Human VEGF-specific oligonucleotides
US6649596B1 (en) 1995-12-08 2003-11-18 Hybridon, Inc. Modified VEGF Oligonucleotides for Inhibition of tumor growth
US7846730B2 (en) 2001-07-17 2010-12-07 Isis Pharmaceuticals, Inc. Antisense modulation of BCL2-associated X protein expression
US7271002B2 (en) 2001-11-09 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US20080188437A1 (en) 2002-07-24 2008-08-07 The Trustees Of The University Of Pennsylvania Compositions and Methods for siRNA Inhibition of Angiogenesis
US20090202490A1 (en) 2003-06-30 2009-08-13 Schaffer David V Mutant adeno-associated virus virions and methods of use thereof
US20050053922A1 (en) 2003-06-30 2005-03-10 Schaffer David V. Mutant adeno-associated virus virions and methods of use thereof
US20050075492A1 (en) 2003-08-07 2005-04-07 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US20050266552A1 (en) 2003-12-05 2005-12-01 Doench John G Reagents and methods for identification of RNAi pathway genes and chemical modulators of RNAi
US7947659B2 (en) 2004-03-12 2011-05-24 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
US7919473B2 (en) 2004-03-12 2011-04-05 Alnylam Pharmaceuticals, Inc. IRNA agents targeting VEGF
US20050272923A1 (en) 2004-05-06 2005-12-08 Zhang Byoung-Tak Mature microRNA prediction method using bidirectional hidden markov model and medium recording computer program to implement the same
US20070261127A1 (en) 2005-07-22 2007-11-08 Boyden Edward S Light-activated cation channel and uses thereof
US20100015095A1 (en) 2006-05-04 2010-01-21 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US20110143400A1 (en) 2006-09-08 2011-06-16 Opko Ophthalmics, Llc Sirna and methods of manufacture
US20150152142A1 (en) * 2009-02-11 2015-06-04 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20130019325A1 (en) 2010-03-17 2013-01-17 Karl Deisseroth Light-Sensitive Ion-Passing Molecules
US20110301073A1 (en) 2010-05-17 2011-12-08 Sangamo Biosciences, Inc. Novel DNA-binding proteins and uses thereof
US20160002302A1 (en) 2010-11-05 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
US20130347137A1 (en) 2010-11-05 2013-12-26 The Board Of Trustees Of The Leland Stanford Junior University Stabilized Step Function Opsin Proteins and Methods of Using the Same
US20140364338A1 (en) 2011-04-22 2014-12-11 The Regents Of The University Of California Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof
US20150315610A1 (en) * 2012-12-25 2015-11-05 Takara Bio Inc. Aav variant
US20160355797A1 (en) 2013-12-12 2016-12-08 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
US20170096683A1 (en) * 2014-05-02 2017-04-06 Genzyme Corporation Aav vectors for retinal and cns gene therapy
WO2016141078A1 (en) 2015-03-02 2016-09-09 Avalanche Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
WO2017197355A2 (en) * 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
WO2019046069A1 (en) 2017-08-28 2019-03-07 The Regents Of The University Of California ADENO-ASSOCIATED VIRUS CAPSID VARIANTS AND METHODS OF USE

Non-Patent Citations (71)

* Cited by examiner, † Cited by third party
Title
"Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis, Selected Methods and Applications", 1988, ALAN R. LISS, INC, pages: 127 - 149
"GenBank", Database accession no. NP_001289
"Methods in Enzymology", vol. 266, 1996, ACADEMIC PRESS, INC., article "Computer Methods for Macromolecular Sequence Analysis"
"Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT, WILLIAMS, & WILKINS
A. GENNARO: "Handbook of Pharmaceutical Excipients", 2000, LIPPINCOTT, WILLIAMS, & WILKINS
ADVANCES IN APPLIED MATHEMATICS, vol. 2, 1981, pages 482 - 489
AKIYAMA ET AL., J. CELL PHYSIOL., vol. 207, 2006, pages 407
BELLAICHE ET AL., GENETICS, vol. 152, 1999, pages 1037
BOOIJ ET AL., OPHTHALMOLOGY, vol. 118, 2011, pages 160 - 167
BURSTEIN ET AL., NATURE, vol. 542, 2017, pages 237
DALKARA, D., KOLSTAD, K. D., CAPORALE, N., VISEL, M., KLIMCZAK, R. R., SCHAFFER, D. V., & FLANNERY, J. G.: "Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 17, no. 12, 2009, pages 2096 - 2102, XP055183686, Retrieved from the Internet <URL:http://doi.org/10.1038/mt.2009.181> DOI: 10.1038/mt.2009.181
DALKARA, D.BYRNE, L. C.KLIMCZAK, R. R.VISEL, M.YIN, L.MERIGAN, W. H. ET AL.: "In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous", SCIENCE TRANSLATIONAL MEDICINE, vol. 5, no. 189, 2013, pages 189 - 76, XP055452295, Retrieved from the Internet <URL:http://doi.org/10.1126/scitranslmed.3005708>
DALKARA, D.GOUREAU, O.MARAZOVA, K.SAHEL, J.-A.: "Let there be light: gene and cell therapy for blindness", HUMAN GENE THERAPY, 2016, Retrieved from the Internet <URL:http://doi.org/10.1089/hum.2015.147>
DAY ET AL.: "Advances in AAV Vector Development for Gene Therapy in the Retina", RETINAL DEGENERATIVE DISEASES: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 801, 25 March 2014 (2014-03-25), pages 1 - 7, XP055623024, DOI: 10.1007/978-1-4614-3209-8_86 *
DEN HOLLANDER ET AL., NAT. GENET., vol. 23, 1999, pages 217
DENIZ DALKARA ET AL.: "In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous", SCIENCE TRANSLATIONAL MEDICINE, vol. 5, no. 189, 12 June 2013 (2013-06-12), pages 1 - 11, XP055533378, DOI: 10.1126/scitranslmed.3005708
DIESTER ET AL., NAT. NEUROSCI., vol. 14, 2011, pages 387
DOROUDCHI ET AL., MOL THER., vol. 19, no. 7, 2011, pages 1212 - 1219
FOWLER ET AL., NAT PROTOC, vol. 9, 2014, pages 2267 - 2284
GAUB, PROC. NATL. ACAD. SCI. USA, vol. 111, 2014, pages E5574
GOROSTIZA ET AL., PROC NATL ACAD SCI USA., vol. 104, 2007, pages 10865 - 10870
GRAINGER ET AL., MOL. THER., vol. 12, 2005, pages S337
HANEN KHABOU ET AL.: "Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8 : Mechanisms of Enhanced Transduction by AAV2-7m8", BIOTECHNOLOGY AND BIOENGINEERING, vol. 113, no. 12, 1 December 2016 (2016-12-01), pages 2712 - 2724, XP055372484, DOI: 10.1002/bit.26031
HEATH ET AL., NATURE STRUCTURAL BIOLOGY, vol. 4, 1997, pages 468
HENRIKSEN ET AL., J. OPHTHALMIC VIS. RES., vol. 9, 2014, pages 374
J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
KAISER ET AL., AM. J. OPHTHALMOL., vol. 150, 2010, pages 33
KLEINSTIVER ET AL., NATURE, vol. 523, 2015, pages 481
KLEINSTIVER ET AL., NATURE, vol. 529, 2016, pages 490
KOERBER ET AL., MOL THER, vol. 17, 2009, pages 2088 - 2095
KOERBER, J. T.JANG, J.-H.SCHAFFER, D. V.: "DNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 16, no. 10, 2008, pages 1703 - 1709, XP055172086, Retrieved from the Internet <URL:http://doi.org/10.1038/mt.2008.167> DOI: 10.1038/mt.2008.167
KOHL ET AL., EUR J HUM GENET., vol. 13, no. 3, 2005, pages 302
KOU ET AL., BIOCHEM., vol. 44, 2005, pages 15064
LAGALI ET AL., NAT NEUROSCI., vol. 11, no. 6, 2008, pages 667 - 675
LAGOS- QUINTANA ET AL., CURRENT BIOLOGY, vol. 12, 2002, pages 735 - 739
LAGOS-QUINTANA ET AL., RNA, vol. 9, 2003, pages 175 - 179
LAGOS-QUINTANA ET AL., SCIENCE, vol. 294, 2001, pages 853 - 857
LEE, PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 18902
LI ET AL., NATURE, vol. 475, 2011, pages 217
LIM ET AL., GENES & DEVELOPMENT, vol. 17, 2003, pages 991 - 1008
LIM ET AL., SCIENCE, vol. 299, 2003, pages 1540
MAGUIRE, A. M., SIMONELLI, F., PIERCE, E. A., PUGH, E. N., JR., MINGOZZI, F., BENNICELLI, J.: "Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis", N ENGL J MED, vol. 358, no. 21, 2008, pages 2240 - 2248, XP055027817, Retrieved from the Internet <URL:http://doi.org/10.1056/NEJMoa0802315> DOI: 10.1056/NEJMoa0802315
MANCUSO ET AL., NATURE, vol. 461, no. 7265, 2009, pages 784 - 787
METH. MOL. BIOL., vol. 70, 1997, pages 173 - 187
MORI ET AL., VIROLOGY, vol. 330, 2004, pages 375
MORIMURA, PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 3088
NAKAZAWA, T., MATSUBARA, A., NODA, K., HISATOMI, T., SHE, H., SKONDRA, D.: "Characterization of cytokine responses to retinal detachment in rats", MOLECULAR VISION, vol. 12, 2006, pages 867 - 878
NAKAZAWA, T.TAKEDA, M.LEWIS, G. P.CHO, K.-SJIAO, J.WILHELMSSON, U. ET AL.: "Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 48, no. 6, 2007, pages 2760 - 2768, Retrieved from the Internet <URL:http://doi.org/10.1167/iovs.06-1398>
NG ET AL., NAT. REV. DRUG DISCOVERY, vol. 5, 2006, pages 123
NI, HUI, OPHTHALMOLOGICA, vol. 223, 2009, pages 401
NICOUD ET AL., J. GENE MED., vol. 9, 2007, pages 1015
PADRON ET AL., J. VIROL., vol. 79, 2005, pages 5047
PECHAN ET AL., GENE THER., vol. 16, 2009, pages 10
PETRS-SILVA, H.DINCULESCU, A.LI, Q.MIN, S.-H.CHIODO, V.PANG, J. J. ET AL.: "High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 17, no. 3, 2009, pages 463 - 471, XP055076954, Retrieved from the Internet <URL:http://doi.org/10.1038/mt.2008.269> DOI: 10.1038/mt.2008.269
REICH ET AL., MOL. VIS., vol. 9, 2003, pages 210
SANTIAGO-ORTIZ ET AL., GENE THER., vol. 22, 2015, pages 934
SANTIAGO-ORTIZ, GENE THER, vol. 22, 2015, pages 934 - 946
SANTIAGO-ORTIZ, J., OJALA, D. S., WESTESSON, O., WEINSTEIN, J. R., WONG, S. Y., STEINSAPIR, A.: "AAV ancestral reconstruction library enables selection of broadly infectious viral variants", GENE THERAPY, vol. 22, no. 12, 2015, pages 934 - 946, XP037771296, Retrieved from the Internet <URL:http://doi.org/10.1038/gt.2015.74> DOI: 10.1038/gt.2015.74
See also references of EP3645052A4
SHEN ET AL., GENE THER., vol. 13, 2006, pages 225
SHEN ET AL., MOL. THER., vol. 15, 2007, pages 1955
SULLIVAN ET AL.: "Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain", GENE THERAPY, vol. 25, no. 3, 22 May 2018 (2018-05-22), pages 205 - 219, XP036536617 *
THYAGARAJAN ET AL., J NEUROSCI., vol. 30, no. 26, 2010, pages 8745 - 8758
TOMITA ET AL., MOL. THER., vol. 22, 2014, pages 1434
TRAVIS ET AL., GENOMICS, vol. 10, 1991, pages 733
VAN BOKHOVEN ET AL., HUM. MOL. GENET., vol. 3, 1994, pages 1041
VAN VLIET ET AL., MOL. THER., vol. 14, 2006, pages 809
VOLGRAF ET AL., NAT CHEM BIOL., vol. 2, 2006, pages 47 - 52
YOKOYAMA ET AL., EXP EYE RES., vol. 55, 1992, pages 225
YOUNG ET AL., OPHTHALMOL. VIS. SCI., vol. 44, 2003, pages 4076
ZOLOTUKHIN ET AL., GENE THER., vol. 6, 1999, pages 973

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US12180500B2 (en) 2014-06-09 2024-12-31 Voyager Therapeutics, Inc. Chimeric capsids
US12454702B2 (en) 2017-04-05 2025-10-28 University Of Massachusetts Minigene therapy
US11739346B2 (en) 2017-04-05 2023-08-29 University Of Massachusetts Minigene therapy
US12146150B2 (en) 2017-09-29 2024-11-19 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
WO2019158619A1 (en) * 2018-02-15 2019-08-22 Bjoerklund Tomas Modified viral capsids
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
US12049648B2 (en) 2018-09-26 2024-07-30 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
US11149256B2 (en) 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
JP7619958B2 (ja) 2019-04-04 2025-01-22 リジェネックスバイオ インコーポレイテッド 組換えアデノ随伴ウイルス及びその使用
JP2022528416A (ja) * 2019-04-04 2022-06-10 リジェネックスバイオ インコーポレイテッド 組換えアデノ随伴ウイルス及びその使用
US12390539B2 (en) 2019-05-20 2025-08-19 University Of Massachusetts Minigene therapy
JP2023504773A (ja) * 2019-10-31 2023-02-07 ウニベルジテート ベルン 眼遺伝子送達のためのａａｖベクター変異体
US12509705B2 (en) 2019-10-31 2025-12-30 Universität Bern AAV vector variants for ocular gene delivery
JP7791546B2 (ja) 2019-10-31 2025-12-24 ウニベルジテート ベルン 眼遺伝子送達のためのａａｖベクター変異体
WO2021084133A1 (en) * 2019-10-31 2021-05-06 Universität Bern Aav vector variants for ocular gene delivery
US12031147B2 (en) 2020-05-29 2024-07-09 The Regents Of The University Of California Adeno-associated virus virions with variant capsids and methods of use thereof
EP4157299A4 (en) * 2020-05-29 2024-10-02 The Regents of the University of California ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSIDS AND METHODS OF USE THEREOF
US12331081B2 (en) 2021-10-08 2025-06-17 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
US12331082B2 (en) 2021-10-08 2025-06-17 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
US12116385B2 (en) 2021-10-08 2024-10-15 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
WO2024191778A1 (en) 2023-03-10 2024-09-19 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2025008323A1 (en) * 2023-07-03 2025-01-09 UCB Biopharma SRL Engineered aav capsid proteins
WO2025049993A1 (en) 2023-08-31 2025-03-06 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2025171227A1 (en) 2024-02-08 2025-08-14 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Also Published As

Publication number Publication date
US20240091378A1 (en) 2024-03-21
CN110461368A (zh) 2019-11-15
AU2023248082B2 (en) 2025-07-10
JP2023126919A (ja) 2023-09-12
AU2018290954A1 (en) 2019-08-29
EP3645052A1 (en) 2020-05-06
EP3645052A4 (en) 2021-07-28
JP7744659B2 (ja) 2025-09-26
AU2018290954B2 (en) 2023-07-13
MX2019010910A (es) 2019-11-07
KR20250023600A (ko) 2025-02-18
AU2023248082A1 (en) 2023-11-02
US12310997B2 (en) 2025-05-27
BR112019019015A2 (pt) 2020-04-14
KR20200022372A (ko) 2020-03-03
KR102766238B1 (ko) 2025-02-13
CA3053154A1 (en) 2019-01-03
US20200121746A1 (en) 2020-04-23
JP2020528734A (ja) 2020-10-01

Similar Documents

Publication Publication Date Title
US12310997B2 (en) Compositions and methods of treating ocular diseases
US11565001B2 (en) Adeno-associated virus virions with variant capsid and methods of use thereof
EP3693025B1 (en) Adeno-associated virus virions with variant capsid and methods of use thereof
US12031147B2 (en) Adeno-associated virus virions with variant capsids and methods of use thereof
HK40051378A (en) Adeno-associated virus virions with variant capsid and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18822630

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3053154

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018290954

Country of ref document: AU

Date of ref document: 20180628

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197027085

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019019015

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019568621

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018822630

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018822630

Country of ref document: EP

Effective date: 20200130

ENP Entry into the national phase

Ref document number: 112019019015

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190913

WWD Wipo information: divisional of initial pct application

Ref document number: 1020257003821

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020257003821

Country of ref document: KR